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1. Summary 
The production and deposition of the cytotoxic Aβ peptide is a central event in the 
pathogenesis of Alzheimer’s disease (AD). Aβ is excised from the amyloid precursor 
protein (APP) through sequential actions of the β-secretase, which cleaves at the so-
called β-site, and the γ-secretase, which cleaves at the so-called γ-site of APP. Inhibition 
the β-secretase BACE1 is a promising approach for AD therapy, but the search for small 
molecule inhibitors has proven to be challenging. In this thesis I describe a novel 
screening assay to identify cell-active BACE1 inhibitors by a positive yeast growth 
selection system, which combines the practicability of in vitro assays with the advantages 
of a cell-based assay. Analogue to the situation in mammalian cells, the β-site cleavage 
reaction was reconstituted in the secretory pathway of yeast cells using membrane-bound 
BACE1 and a membrane-bound APP-derived substrate. In contrast to conventional 
mammalian cell-based assays, false positive compounds can be rapidly excluded by the 
use of simple specificity controls that mimic the readout in the absence of BACE1. 
Furthermore, there is counter-selection for toxic compounds due to the positive growth 
readout upon inhibition of BACE1. The system was initially validated with two bona fide 
BACE1 inhibitors that stimulated the growth of BACE1-expressing cultures in a 
concentration-dependent manner, whereas the growth of control cultures remained 
unaffected in the presence of these inhibitors. In order to identify novel BACE1 inhibitors 
and to further validate the system, we screened a library of 15’000 small molecules. This 
screening revealed six compounds, which significantly reduced the secretion of Aβ from 
a human cell line overexpressing APP.  
 2
1. Zusammenfassung 
In der Entstehung der Alzheimer’schen Krankheit spielt das zytotoxische Peptid Aβ eine 
zentrale Rolle. Zwei aufeinanderfogende Schnitte, welche durch die sogenannte β- und γ-
Sekretase ausgeführt werden, setzen das Aβ Peptid aus dem Amyloid Precursor Protein 
(APP) frei. Die Inhibierung der β-Sekretase BACE1 ist ein vielversprechender Ansatz für 
die Therapierung der Alzheimer’schen Krankheit. Leider hat sich die Identifizierung von 
BACE1 Inhibitoren mittels bestehender Screening-Methoden als schwierig erwiesen. In 
der vorliegenden Arbeit beschreibe ich eine neuartige Methode für die Identifizierung 
von BACE1 Inhibitoren mittels einer positiven Wachstumsselektion von Hefezellen. 
Diese Methode kombiniert die einfache Durchführbarkeit von in vitro Methoden mit den 
Vorteilen von Zell-basierten Methoden. Für die Rekonstituierung der proteolytischen 
Reaktion der β-Sekretase wurden BACE1 und ein APP-basiertes Substrat als 
membranständige Proteine in sekretorischen Kompartimenten der Hefe exprimiert. Dies 
ist analog zu der natürlichen Situation in menschlichen Zellen. Im Gegensatz zu 
herkömmlichen Screening-Methoden mit kultivierten Säugetierzellen, bietet das 
Hefesystem Möglichkeiten, die es erlauben falsch-positive Substanzen mittels einfacher 
Spezifizitätskontrollen auszuschliessen. Die positve Wachstumsantwort, welche auf die 
Inhibierung von BACE1 erfolgt, verhindert zudem die Selektion von toxischen 
Substanzen. Das Hefesystem wurde mit Hilfe von zwei bestehenden BACE1-Inhibitoren 
validiert. Beide Inhibitoren ergaben eine konzentrationsabhängige Wachstumsantwort in 
BACE1-exprimierenden Hefezellen, während das Wachstumsverhalten von Hefezellen, 
die eine BACE1-unabhängige Kontrolle exprimierten, durch die Inhibitoren nicht 
beeinflusst wurde. Mit der Absicht, neuartige BACE1-Inhibitoren zu identifizieren und 
das Hefesystem weiter zu validieren, wurde ein Screening von 15'000 chemischen 
Verbindungen durchgeführt. In diesem Screening wurden sechs chemische Verbindung 
identifiziert, welche die Aβ-Sekretion einer APP-überexprimierenden humanen Zelllinie 
signifikant reduzierten. 
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2. Introduction 
2.1. Alzheimer’s disease: A short introduction 
Alzheimer’s disease (AD) is a progressive disease of the brain leading to loss of 
cognitive functions and ultimately to death. The major risk factor for the disease is age. 
The incidence of AD rises exponentially with age (Kawas et al., 2000) and therefore the 
increased life expectancy of human beings has made AD one of the predominant medical 
problems for elderly people. The disease is named after Alois Alzheimer (1864-1915). In 
1906 he described a female patient in her early 50s, who suffered from progressive 
problems with memory, language and behavior. After the patient died, Alzheimer found 
two major changes in her brain, which he called neurofibrillary tangles and amyloid 
plaques.  
Neurofibrillary tangles and amyloid plaques are hallmarks of the disease and the 
elucidations of their molecular compositions were milestones towards a profound 
understanding of the mechanism underlying the disease. The neurofibrillary tangles 
(NFT) are intracellular aggregates of hyperphosphorylated versions of the microtubule-
associated protein tau (Wood et al., 1986; Wischik et al., 1988; Lee et al., 1991). The 
major component of the extracellular amyloid plaques is the β-amyloid peptide (Aβ) 
(Masters et al., 1985), which is excised from the so-called amyloid precursor protein 
(APP) (Kang et al., 1987) through sequential cleavage by the β- and the γ-secretases. 
Cleavage at the so-called α-site in the middle of the Aβ sequence precludes β-secretase 
cleavage and gives rise to the shorter non-amyloidogenic p3 peptide (Figure 1, for review 
see Selkoe, 2001). 
Soon the question came up, which of the two hallmarks occurs first in the course of the 
disease and hence, which is the causative agent. The “tauists” believed that 
hyperphosphorylated tau occurs first and that Aβ-deposition is a consequence of it, 
whereas the “βabtists” claimed that it is the other way round. 
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Figure 1 Proteolytic processing of the type-I transmembrane protein APP. The cleavage 
sites of the α-, β- and γ-secretase are indicated by α, β and γ. The amyloidogenic 
pathway is initiated by cleavage of APP at the β-site, which gives rise to two proteolytic 
fragments: The soluble APP ectodomain sAPPβ and the membrane-bound C-terminal 
fragment CTFβ. Subsequent cleavage of the γ-secretase at position 40 or 42 within the 
transmembrane domain (TM) of APP releases Aβ40 or Aβ42. The non-amyloidogenic 
pathway is initiated by α-secretase cleavage of APP giving rise to sAPPα and CTFα. 
Subsequent γ-secretase cleavage releases the non-amyloidogenic p3 peptide. The 
indicated numbers refer to Aβ numbering. 
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The importance of neurofibrillary tangles was emphasized by the recognition, that there 
exists a whole group of neuropathological disorders with filamentous intracellular 
inclusions composed of hyperphosphorylated tau. A prominent member of these so-called 
“tauopathies” is the autosomal dominant fronto temporal dementia with parkinsonism 
linked to chromosome 17 (FTDP-17), for which mutations could be mapped to the tau 
gene on chromosome 17 (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 
1998). The most common mutation in FTDP-17, the tau P301L was expressed in 
transgenic mice, which exhibited motor and behavioral deficits and developed NFTs in 
an age and gene-dose-dependent manner (Lewis et al., 2000; Götz et al., 2001a). These 
findings demonstrate that aberrant tau processing can be sufficient to cause dementia. In 
the case of AD however, this is not yet the whole story. If the mice expressing tau P301L 
are crossed with mice expressing mutant APP (Tg2576), or if Aβ peptide is injected into 
their brains, the number of NFTs becomes several fold enhanced (Götz et al., 2001b; 
Lewis et al., 2001), which are strong arguments for Aβ playing a central role in the 
development of AD.  
2.2. Putative mechanism of Aβ toxicity 
It is known for a long time that Aβ is neurotoxic in vitro (Yankner et al., 1990) and in 
vivo (Kowall et al., 1992). However the exact mechanism of this toxicity remains unclear. 
The literature is often contradictive in the details, but the following minimal consensus 
seems to be widely accepted: Aβ toxicity is associated with oxidative stress, which 
causes oxidative damage to macromolecules such as proteins, nucleic acids and lipids, 
and which then leads to apoptosis. (Signs of necrotic cell death have been observed as 
well in the AD brain, but most publications describe prevalence for apoptotic cell death 
implicated in AD.)  
How is Aβ associated with enhanced occurrence of reactive oxygen species (ROS) that 
cause oxidative stress? Does it generate the harmful ROS directly or indirectly? Many 
studies describe a disturbance of the intracellular Ca2+ homeostasis that goes along with 
Aβ toxicity (for review see Canevari et al., 2004). Since Ca2+ signals play a fundamental 
role as coordinators and integrators of cellular signaling pathways, they represent a good 
candidate as mediator for the manifestation of pathological processes. However, the 
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causal relationship of oxidative stress and the disturbance of Ca2+ homeostasis is 
contradictive. Are the observed changes in intracellular Ca2+ concentration directly 
caused by Aβ, and oxidative stress results as a consequence of it, or is the disturbance of 
the Ca2+ homeostasis a consequence of oxidative stress? Models supporting a direct role 
for Aβ in disturbing Ca2+ homeostasis suggest that Aβ alters the current through Ca2+ 
channels or that it directly alters the leakiness of the membrane for Ca2+, e.g. by the 
formation of a pore.  
A direct role for the generation of oxidative stress by Aβ is supported by the 
observation that Aβ binds Cu(II) with very high affinity and that this complex catalyzes 
the production of cytotoxic hydrogen peroxide (H2O2) via the reduction of Cu(II) to Cu(I) 
(Huang et al., 1999a; Huang et al., 1999b). Furthermore, it was shown that this reaction 
depends on the presence of a reducing agent like dopamine, cholesterol or vitamin C 
(Opazo et al., 2002). The cytotoxic effect of the Aβ⋅Cu(II) complex could be attenuated 
by the addition of catalase, which catalyzes the reaction of 2 H2O2 to yield 2 H20 and O2. 
Beside neurotoxic effects there is also a number of publications describing neurotrophic 
effects of Aβ (for review see Atwood et al., 2003). Atwood et al. summarize evidence 
that Aβ can protect neurons from Fe(II) induced toxicity by binding to it and that it can 
function as antioxidant with superoxide dismutase (SOD)-like activity that catalyzes the 
reduction of superoxide (O2-) to H2O2. In this view, the transition of Aβ from a 
neuroprotective to a neurotoxic factor is concentration and age dependent. At a certain 
concentration of active Aβ complexes the generation of H2O2 would exceed the removal 
capacity of catalase and glutathione peroxidase resulting in cell damage. An analogous 
scenario is known for the Cu,Zn-SOD, which reduces oxidative stress when its activity is 
in balance with catalase activity, but when it is overexpressed relative to catalase activity, 
oxidative stress is increased (Amstad et al., 1991).  
2.3. Therapeutic approaches to reduce Aβ  
Interference with the generation or deposition of Aβ is considered as a promising 
approach for AD therapy. An obvious method to interfere with the production of Aβ is 
inhibiting the secretases, which excise it from APP. The identities of these secretases 
have been revealed in recent years. Five groups published almost simultaneously the 
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identification of the β-secretase BACE1 (β-site APP cleaving enzyme 1; alternative 
names are memapsin 2 or Asp 2), which is a single type-I transmembrane aspartic 
protease (Hussain et al., 1999; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999; 
Lin et al., 2000). BACE1 as a drug target and the search for inhibitors thereof are 
discussed in a separate chapter of this introduction.  
The elucidation of the composition of the γ-secretase, which is a multimeric 
transmembrane complex comprised of presenilin, nicastrin, aph-1 and pen-2 was 
achieved recently (Edbauer et al., 2003; Kimberly et al., 2003). In the absence of 
presenilin 1 (PS1), γ-secretase cleavage of APP is prevented (De Strooper et al., 1998), 
but the gene knockout mice exhibit severe defects of the skeleton and of the CNS, and die 
shortly after birth (Shen et al., 1997; Wong et al., 1997). Indeed, their phenotype is 
strongly reminiscent of the one exhibited by mice deficient for Notch (Wong et al., 
1997), which is a substrate for the γ-secretase as well (De Strooper et al., 1999; Struhl 
and Greenwald, 1999; Ye et al., 1999). An induced knockout of Notch function in mice 
after birth caused a severe deficiency in thymocyte development (Radtke et al., 1999). 
Beside Notch and APP, there are several other targets of the γ-secretase known (for 
review see Medina and Dotti, 2003). For these reasons, inhibition of γ-secretase is 
associated with the risk of adverse side effects. Indeed, ex vivo and in vivo studies with γ-
secretase inhibitors revealed severe interference with lymphopoiesis (Hadland et al., 
2001; Wong et al., 2004). These side effects could be circumvented by developing γ-
secretase inhibitors that specifically affect APP processing, or by finding a range of 
inhibition, which sufficiently impairs Aβ production, but still allows for the biological 
function of the other targets of the γ-secretase. In fact, there are already potent γ-secretase 
inhibitors tested in clinical trials (see for example: http://www.myriad.com/pharma/ 
clinicaltrials/alzheimers.htm or http://www.centerwatch.com/bookstore/nmt/nmtb_ 
alzheimers.pdf). 
Another possibility to reduce Aβ would be to shift APP processing from the 
amyloidogenic to the non-amyloidogenic pathway. This approach is especially attractive, 
because it has been shown that the soluble APP ectodomain released by the α-secretase 
(sAPPα) has neuroprotective effects (Furukawa et al., 1996). There are three members of 
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the ADAMs (a disintegrin and metalloproteinase) family (ADAM9, ADAM10 and 
ADAM17), which fulfill the criteria required of α-secretase (for review see Allinson et 
al., 2003).  
At the moment, the only FDA-approved AD drugs are acetylcholine esterase inhibitors, 
which stabilize acetylcholine levels in the brain. Treatment with these drugs does not 
stop, but slows down the progression of the disease and thereby the decline of cognitive 
impairment. There is evidence that the beneficial effect of these drugs is not only due to 
enhanced cholinergic neurotransmission, but also that acetylcholine upregulates the 
production of sAPPα, possibly via an agonistic effect on cholinergic muscarinic 
receptors. Agonists of muscarinic receptors are known to stimulate the production of 
sAPPα (for review see Allinson et al., 2003).  
Retrospective clinical studies on cholesterol-lowering drugs and on NSAIDs (non-
steroidal anti-inflammatory drugs) revealed a reduced risk for developing AD upon 
chronic treatment with these drugs (Rich et al., 1995; Jick et al., 2000; Wolozin et al., 
2000). Increased cholesterol levels are a known risk factor for AD (Kuo et al., 1998) and 
there is evidence that high cholesterol levels shift the balance of amyloidogenic and non-
amyloidogenic APP processing to the amyloidogenic pathway (for review see Allinson et 
al., 2003). For a subset of NSAIDs it was shown that they directly inhibit the γ-secretase 
(Eriksen et al., 2003), however for others it has been demonstrated that they upregulate 
the non-amyloidogenic pathway via activation of the Erk MAP kinase signaling cascade 
(Avramovich et al., 2002). 
The role of a forth secretase, the BACE1 homologue BACE2 (71% sequence 
homology; Acquati et al., 2000), in the amyloidogenic pathway is less clear at the 
moment. Upon overexpression, BACE2 cleaves at the β-site and more efficiently at 
alternative sites near the α-site, after Phe-19 and Phe-20 of the Aβ sequence (Farzan et 
al., 2000; Hussain et al., 2000). The Flemish mutation at residue 21 increases the 
proportion of β-site cleavage by BACE2 (Farzan et al., 2000), which is an indicator that 
BACE2 can be involved in amyloidogenic processing of APP. However, overexpression 
of BACE2 caused an increased release of β-secretase derived soluble APP ectodomain 
(sAPPβ), but this was not accompanied by increased secretion of Aβ (Hussain et al., 
2000). Selective inactivation of BACE1 and BACE2 transcripts using RNA interference 
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(RNAi) revealed antagonistic effects of BACE1 and BACE2 (Basi et al., 2003). 
Interference with BACE1 expression caused a decrease of Aβ secretion (as expected), 
whereas interference with BACE2 expression caused an increase of Aβ secretion 
suggesting an analogous role for BACE2 in the amyloidogenic process as for the α-
secretase. Concomitant reduction of BACE1 and BACE2 transcripts did not have any 
effect on Aβ secretion (Basi et al., 2003). These results point out the potential importance 
of developing inhibitors, which are highly specific for BACE1, as they suggest that 
inhibitors, which inhibit both, BACE1 and BACE2 could compromise the desired 
lowering of Aβ. 
An alternative therapeutic approach for reducing adverse effects of Aβ does not involve 
altering the proteolytic processing of APP, but is based on active or passive immunization 
against Aβ. Since the first discovery of beneficial effects of active Aβ-immunization in 
an APP-transgenic mouse model of AD (Schenk et al., 1999), there have followed many 
more promising studies in mice and humans (for review see Dodel et al., 2003). In 2002 a 
phase IIa clinical study for active immunization was suspended due to signs of 
meningoencephalitis in several patients (Senior, 2002). The exact cause for this adverse 
reaction of the vaccination is not yet clear, but is topic of intense investigations. Not clear 
as well are the mechanism by which the beneficial effects of the immunization approach 
are caused. There exist at least three hypotheses (Dodel et al., 2003). The first one 
predicts that the antibodies have to be present in the brain, where they directly bind to 
aggregated Aβ and thereby trigger Fc-mediated phagocytosis of aggregated Aβ. The so-
called peripheral sink hypothesis is based on the assumption that there exists a dynamic 
equilibrium between Aβ in the brain, in the cerebral spinal fluid (CSF) and in the plasma. 
Aβ⋅antibody complex formation in the plasma would therefore cause an Aβ efflux out of 
the brain. The third predicted mechanism, involves direct inhibition of Aβ-aggregation 
and neurotoxicity by the antibodies. 
Recent findings suggest that inhibition of kinases could be an approach to reduce the 
production of Aβ. It was found that the kinase inhibitor gleevec (STI571) reduced Aβ 
production in rat primary neuronal cultures and in vivo in guinea pig brain (Netzer et al., 
2003). The exact mode of action for this has not yet been determined. Although it was 
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shown that the effect is dependent on the presence of ATP, it can still be that it does not 
involve the inhibition of a kinase. Remarkably, it was shown that gleevec interferes with 
γ-secretase processing of APP, but not with γ-secretase processing of Notch (Netzer et al., 
2003). Similarly, it was found that therapeutic concentrations of lithium, a known 
inhibitor of glycogen synthase kinase-3 (GSK-3), interfere with γ-secretase processing of 
APP, but not of Notch (Phiel et al., 2003). The authors of this study furthermore 
demonstrated that overexpression of GSK-3α causes an increased secretion of Aβ. GSK-
3 is also one of the kinases found to hyperphosphorylate tau (Hanger et al., 1992) and 
therefore its inhibition is especially interesting for AD therapy, since it could affect both, 
amyloid deposition and neurofibrillary pathology. 
2.4. BACE1 as a drug target for AD therapy 
As discussed above, inhibition of the γ-secretase can be problematic due to interference 
with the Notch (and eventually other targets of the γ-secretase) signaling pathway. For 
BACE1 inhibition, the issue of side effects could not yet be addressed, since there are no 
publications about BACE1 inhibitors being active in an animal model. The data obtained 
from BACE1 knockout mice, however, are promising. Gene knockout mice for BACE1 
do not produce any detectable amounts of Aβ. Furthermore, these mice do not exhibit any 
obvious developmental defects indicating that inhibition of this enzyme would probably 
reduce Aβ production, without causing any severe side effects (Cai et al., 2001; Luo et 
al., 2001; Roberds et al., 2001; Luo et al., 2003). A minor behavioral phenotype of 
BACE1 knockout mice, however, was detected. Harrison et al. found that their knockout 
mice were more timid and less exploratory than their wildtype littermates (Harrison et al., 
2003). Apart from APP, there are two other targets of BACE1 described in the literature, 
the Golgi resident sialyltransferase ST6Gal I and the P-selectin glycoprotein ligand-1 
(PSGL-1), which are both involved in the regulation of the immune system (Kitazume et 
al., 2001; Lichtenthaler et al., 2003). The gene knockout mice for ST6Gal I or PSGL-1 
are both viable (Hennet et al., 1998; Xia et al., 2002), but unlike the BACE1 knockout 
mice they exhibited immune system related phenotypes, which indicates that the 
functions of these two proteins are not fully dependent on BACE1 activity. 
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From a biological point of view BACE1 is widely considered as potentially ideal 
therapeutic target for the treatment of AD (see for example: Cai et al., 2001; Luo et al., 
2001; Roberds et al., 2001; Hong et al., 2002a; John et al., 2003; Citron, 2004)). Hook 
and Reisine however challenge this view and provide evidence that β-site processing of 
APP could in addition to BACE1 also be accomplished by as yet unidentified cysteine 
proteases. According to their model, Aβ produced by BACE1 would be secreted via the 
(minor) constitutive secretion pathway, whereas Aβ produced by these cysteine proteases 
would be secreted via the (major) regulated secretion pathway of neurons, which can be 
stimulated by neurotransmitters or changes in electrical firing activity (Hook et al., 2002; 
Hook and Reisine, 2003). 
From a pharmacological point of view BACE1 has proven to be a tough target. The 
requirement of therapeutic BACE1 inhibitors to penetrate the blood-brain barrier would 
be best met by nonpeptidic compounds of low molecular weight. However, extensive 
campaigns of big pharma companies to identify small molecule inhibitors of BACE1 by 
random screenings of huge compound collections have had limited success so far (see 
also part 2.6. of this thesis, Middendorp et al. 2004). There are patents from Takeda, 
Vertex and Neurologic that disclose structures of nonpeptidomimetic compounds (for 
review see John et al., 2003). The most potent inhibitor claimed by Takeda reveals an in 
vitro IC50 of 0.35 µM, the most potent compound from Vertex has a Ki of 3 µM. The 
compounds disclosed by Neurologic were shown to shift β-site processing of APP to the 
non-amyloidogenic α-secretase pathway, which is – although a promising result for a 
potential AD therapy anyway – not a clear proof that these compounds target BACE1. 
The best progress towards therapeutic inhibitors of BACE1 has been achieved using 
rational approaches. The elucidations of the structures of the BACE1 ectodomain in 
complex with two different inhibitors (Hong et al., 2000; Hong et al., 2002b) and most 
recently of free BACE1 ectodomain (Hong and Tang, 2004) provided important 
information for these approaches. A second essential achievement to aid rational 
approaches was the determination of the subsite specificity of BACE1 using a 
combinatorial peptide library (Turner et al., 2001). Exploiting the subsite specificity 
information yielded a very potent inhibitor consisting of an eight amino acid peptide, in 
which the peptidic bond between the p1 and the p1’ residue was replaced by an 
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uncleavable hydroxyethylene transition state isostere. The Ki of this compound is 0.31 
nM (Turner et al., 2001). It has not been reported to have an effect in cell culture, but it 
can be used as a lead structure for designing smaller and potentially cell-permeable, 
peptidomimetic inhibitors. 
Elan Pharmaceuticals successfully developed a peptide inhibitor with an uncleavable 
statine group into a cell-permeable statine-based peptidomimetic inhibitor, which reduced 
the production of Aβ in HEK 293 cells by 50% at a concentration of 4 µM (EC50 = 4 µM) 
(Hom et al., 2003). A more recent publication from Elan Pharmaceuticals reports an even 
improved statine-based compound displaying an IC50 of 1 nM and an EC50 of 1000 nM 
(Hom et al., 2004). Furthermore, they produced a series, in which the statine groups were 
replaced by hydroxyethylene isosteres. The best compound of this series revealed IC50 
and EC50 values of 30 nM and 3000 nM, respectively (Hom et al., 2004). The authors 
pointed out that the EC50 to IC50 ratio was a factor of 1000 for the statine-based 
compound, whereas this factor was only 100 for the hydroxyethylene-based compound, 
suggesting that the hydroxyethylene-based compound displays a better cell-permeability. 
In summary, considerable progress has been achieved with peptidomimetic inhibitors of 
BACE1, whereas there is limited information about non-peptidomimetic compounds. 
However, the identification of a non-peptidomimetic lead structure is still desirable. The 
last part of this introduction summarizes existing screening methods and previews the 
work of this thesis, a novel screening system in yeast to identify inhibitors of BACE1. 
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Abstract
The b-secretase BACE1 is an attractive drug target for
reducing the level of the Alzheimer’s disease-promoting
Ab peptide in the brain. Whereas potent peptidomimetic
in vitro inhibitors of BACE1 have been designed, screen-
ing approaches to identify cell-permeable small molecule
inhibitors have had limited success so far. In the present
minireview we summarize existing screening methods,
discuss their scope of application in the drug discovery
process and compare them to a novel cell-based screen-
ing system to identify BACE1 inhibitors by a positive
yeast growth selection.
Keywords: Ab; Alzheimer’s disease; BACE1;
b-secretase; b-secretase inhibitor; screening system.
Introduction
Alzheimer’s disease (AD), the most common cause for
senile dementia, is characterized by two neuropatholog-
ical lesions in the brain: Neurofibrillary tangles and amy-
loid plaques. The major component of the amyloid
plaques is aggregated amyloid b (Ab) peptide, which is
excised from the type-I transmembrane protein amyloid
precursor protein (APP) through sequential cleavage by
the b- and the g-secretase. An alternative cleavage at
the so-called a-site precludes b-site cleavage and gives
rise to the shorter, non-toxic p3 peptide. The amyloid
cascade hypothesis states that the Ab peptide is the
central trigger in the pathogenesis of AD (Citron, 2004).
Indeed, most of the current approaches towards an AD
therapy aim to inhibit the production or deposition of the
cytotoxic Ab peptide (Michaelis, 2003). Inhibition of the
b- or g-secretase is a straightforward strategy to achieve
this goal and consequently, extensive endeavors have
been undertaken for their identifications. The search for
the g-secretase revealed a transmembrane protein com-
plex composed of nicastrin, Pen-2, Aph-1 and presenilin-
1 (PS1), the latter being the suspected enzymatic subunit
(Edbauer et al., 2003). For the g-secretase there exist
already potent inhibitors, which reduce secreted Ab pep-
tide in AD mouse models (Dovey et al., 2001; Wong et
al., 2004). However, chronic treatment of mice with one
of these inhibitors caused severe side effects, most prob-
ably by interference with the Notch signaling pathway,
which depends on g-secretase activity (Wong et al.,
2004). It remains to be seen whether a therapeutic win-
dow can be found for g-secretase inhibition, in which the
production of Ab peptides is sufficiently reduced to be
therapeutically beneficial, but Notch signaling still can
occur.
The search for the b-secretase revealed a type-I trans-
membrane aspartic protease termed b-site APP cleaving
enzyme (BACE) 1 (Vassar and Citron, 2000). Furthermore,
recent studies published by Hook and Reisine suggest
that, in addition to BACE1, there are cysteine proteases
involved in the b-site processing of APP. These yet uni-
dentified cysteine proteases are relevant for the produc-
tion of Ab peptide in the regulated secretion pathway of
chromaffin cells, whereas the Ab peptide produced by
BACE1 is mainly secreted through the constitutive secre-
tion pathway (Hook and Reisine, 2003). Since there are
no publications about specific b-secretase inhibitors
being active in mouse models, the therapeutic potential
of b-secretase inhibitors can so far only be estimated
from results obtained with BACE1 gene knockout mice.
In support of BACE1 as an important target for devel-
oping b-secretase inhibitors is the observation that
BACE1 knockout mice do not produce any detectable
amounts of Ab peptide. In addition, these mice are via-
ble, fertile, and behave like their wild-type littermates (Cai
et al., 2001; Luo et al., 2001) indicating that treatment
with a BACE1 inhibitor would not cause any severe side
effects. The best progress towards efficient and cell-per-
meable inhibitors of BACE1 has been achieved so far by
the use of peptidic transition state mimetic compounds
(Hom et al., 2003), whereas there are no publications
describing the successful screening of a collection of
small compounds to identify BACE1 inhibitors. In the
present minireview we describe current methods to mon-
itor b-secretase activity and discuss their scope of appli-
cation in the drug discovery process. We compare
existing screening methods and discuss a novel cell-
based screening system to identify BACE1 inhibitors by
a positive yeast growth selection. A link of current meth-
ods is provided in Table 1.
Biochemical methods to monitor BACE1
activity
The identification of BACE1 as b-secretase allowed the
establishment of biochemical methods to investigate
b-secretase activity of recombinant BACE1 in vitro. Nat-
urally, this reaction involves at least two membrane-
bound proteins that interact with each other: BACE1 and
its substrate APP. Since purification of large amounts of
482 O. Middendorp et al.
Table 1 Overview of current methods to monitor b-secretase activity.
b-secretase Substrate Readout Purpose
Biochemical methods
FRET soluble BACE1 modified peptide continuous, direct HTS, kinetics, hit validation
HPLC/MS soluble BACE1 (modified) peptide discontinuous, direct hit validation, kinetics
ELISA soluble BACE1 soluble fusion protein discontinuous, indirect hit validation, kinetics (MTS)
Cell-based assays
Ab ELISA endogenous b- full-length APP discontinuous, MTS, hit validation
secretase indirect (standard test for
cell activity)
Cleavage-dependent secretion of AP
mammalian cells endogenous b- membrane-bound AP- discontinuous, indirect MTS
secretase APP fusion protein
insect cells transgenic BACE1 membrane-bound b-site- discontinuous, indirect MTS
AP fusion protein
Growth readout in yeast cells transgenic BACE1 membrane-bound continuous, indirect MTS-HTS
invertase-APP fusion
protein
Abbreviations: HTS, high-throughput screening; MTS, medium-throughput screening; AP, alkaline phosphatase
membrane-bound proteins is intricate, BACE1 activity
was reconstituted in vitro using soluble BACE1 fragments
and soluble substrates. Soluble BACE1 fragments com-
prising the prodomain (which is removed after folding of
the protein in certain expression systems) and the cata-
lytic domain, but lacking the transmembrane domain and
the cytosolic part were purified from various expression
systems, including 293T cells, E. coli and Drosophila S2
cells. In a recently published study the enzymatic activi-
ties of these soluble BACE1 versions were compared to
the b-secretase activity of membrane preparations from
HEK 293 cells that over-expressed full-length BACE1
(Kopcho et al., 2003). The authors did not find significant
differences between the soluble and the membrane-
bound BACE1 versions regarding enzymatic activity and
inhibition by peptidic transition state mimetic inhibitors.
However, the substrates used for this study were three
peptides of 9 to 27 amino acids of length, which is still
crucially different from the natural situation, in which both
BACE1 and its substrate APP are membrane-bound. It
remains to be seen, whether inhibition of BACE1 cleav-
age measured with soluble substrates is comparable to
inhibition determined with membrane-bound substrates,
or whether the membrane-anchoring properties of the
substrate could be important for the activity of certain
inhibitors. Indeed, all of the most common in vitro meth-
ods to detect BACE1 activity involve soluble substrates.
The majority of the in vitro high-throughput screening
(HTS) systems to identify inhibitors of BACE1 is based
on fluorescence detection methodologies. Fluorescence-
based readouts allow for rigorous assay miniaturization;
especially emerging confocal detection systems for HTS
applications enable to use assay volumes in the submi-
croliter range without loss of signal quality (Ja¨ger et al.,
2003). The most common fluorescence-based methods
involve fluorescent resonance energy transfer (FRET)
substrates. These substrates are peptides with a fluores-
cent group and a quenching group attached to it. Upon
cleavage of the peptide the fluorescent group is sepa-
rated from the quenching group, which results in an
increase of fluorescence (Ermolieff et al., 2000). This kind
of assay is homogenous, direct and continuous, and
therefore allows for online recording of the enzymatic
reaction. The most frequent problem of FRET readouts
is optical interference of the test substances, which can
lead to both, false negative and false positive signals.
This problem can be down-sized by the use of a time-
resolved fluorescence (TRF) readout. Since most fluores-
cence signals from small molecules found in compound
collections have short emission lifetimes and are emitted
at near-UV wavelengths, they can be distinguished from
TRF signals, which have long emission lifetimes and are
emitted at higher wavelengths (Kennedy et al., 2003).
Other frequently used in vitro methods to measure
BACE1 activity involve the quantification of cleavage
products by high-performance liquid chromatography
(HPLC; Toulokhonova et al., 2003), mass spectroscopy
(MS; Turner et al., 2001) or ELISA (Sinha et al., 1999).
These methods are discontinuous and because of their
limited throughputs they are not the first choice for a
HTS. In return, these assays are generally quite robust
and consequently they are used to validate and charac-
terize the hits obtained from the primary screening.
Cellular assays to monitor APP cleavage
Biochemical assays have some evident advantages over
cellular assays. The most obvious of them are higher-
throughput and, in comparison to cellular assays, less
unknown parameters resulting in better controllability and
reproducibility of the assay. On the other hand, cellular
assays cover issues that cannot be addressed by bio-
chemical assays. One important advantage of cell-based
assays is that the target protein and its interaction part-
ners are produced by the cells and presented under
physiological conditions in their native conformation to
the test substance. The potential relevance of this issue
is demonstrated for example by the ‘magic cancer bul-
let’, the kinase inhibitor gleevec (STI-571). Gleevec binds
to the inactive form of kinases (Schindler et al., 2000),
which is in equilibrium with the active form in vivo. How-
ever, most in vitro kinase assays employ the active form,
for which gleevec is a poor inhibitor (Bohmer et al., 2003).
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The second advantage of cell-based HTS is that they
directly select for compounds that are active in the
appropriate cellular compartment. This suggests that
respective compounds are not only able to permeate bio-
logical membranes, but that they are also resistant
against inactivation by enzymes of the cellular metabo-
lism. However, it has to be stated that in the case of in
vitro HTS for BACE1 inhibitors, membrane permeability
is not yet an issue, since BACE1 proved to be a tough
target and it first seems to be a problem to identify any
potent small molecule inhibitor by in vitro screenings.
A well-established method to monitor APP cleavage in
whole cells is provided by a sandwich ELISA that allows
quantifying the amount of Ab present in biological fluids
or released to the medium of cultured cells. This assay,
which is not target-specific, was extensively used to
screen for substances that lower Ab secretion, even
before the identities of b- and g-secretase were revealed.
These screening campaigns resulted in the identification
of several compounds that reduced the amount of Ab in
the supernatant of cultured cells, but none of them was
developed into approved AD therapy drugs and none of
them targeted the b-secretase. However, a recent ELISA-
based screening of 25 000 compounds yielded a lead
compound for g-secretase inhibition, which could be fur-
ther developed to be effective in an animal model (Dovey
et al., 2001).
The ELISA approach enables to differentiate between
Ab40 and the two amino acids longer Ab42 peptide by
the use of specific antibodies. This provides an oppor-
tunity to screen for substances that selectively inhibit the
production of the longer and more aggregation-prone
Ab42, which is considered to be critical for the devel-
opment of the disease (Citron, 2004). A HTS system
based on this concept was established and the screen-
ing of a selection of natural product extracts revealed an
extract that selectively reduced secretion of Ab42 (Yager
et al., 2002).
An alternative concept to monitor b-secretase activity
of entire cells involves the cleavage-dependent release
of a reporter enzyme, generally alkaline phosphatase
(AP), from a chimeric transmembrane protein. The AP
moiety, which is oriented to the topologically extracellular
space, is connected to the membrane via a portion of
APP harboring the b-site. Cleavage at the b-site liberates
the AP moiety, which is then secreted to the cell culture
medium. The activity of the secreted AP molecules is an
indicator for the activity of the b-secretase and can be
quantified by a colorimetric reaction. For a b-secretase
inhibitor screening, this method has the advantage that
it allows to exclude false positives by the use of a cell
line that expresses constitutively secreted AP instead of
membrane-bound AP. If a compound produces a positive
signal (a reduction of the secreted AP activity) with both
cell lines, it does obviously not affect b-secretase, but
interferes somewhere else with the readout, e.g. with the
secretion or catalytic function of AP. An application of this
system is described in a patent from Schering (Dyrks et
al., 1998). We do not have information whether this assay
has been successfully applied in a HTS format. However,
for other purposes, this concept of cleavage-dependent
secretion of AP has been successfully used, e.g. to clone
the SREBP-cleaving protease S1P (Sakai et al., 1998) or
to identify an inhibitor of L-selectin ectodomain shedding
(Feehan et al., 1996). Recently, this concept was also
exploited to establish a screening system for BACE1
inhibitors in Drosophila S2 cells (Oh et al., 2003).
The identification of BACE1 as b-secretase was a pre-
requisite to establish target-specific assays in heterolo-
gous systems like Drosophila or yeast cells, which do not
express endogenous b-secretase activity. In the last sec-
tion of this minireview we describe a novel method to
monitor a reduction of BACE1 activity in the yeast Sac-
charomyces cerevisiae by a positive growth selection.
Positive growth selection system to identify
BACE1 inhibitors in yeast
Heterologous expression of disease-relevant proteins in
yeast allows setting up target-specific screening plat-
forms in an isolated but eukaryotic in vivo system, which
can be suitable for the identification of small molecule
inhibitors against a broad spectrum of proteins (Young et
al., 1998; Grozinger et al., 2001; Perkins et al., 2001;
Zaks-Makhina et al., 2004). BACE1 activity was recon-
stituted in yeast with the aim to establish a target-specific
cell-based HTS system with minimal liquid handling
requirements to identify inhibitors of BACE1. Function-
ality and specificity of an engineered BACE1 variant in
yeast was demonstrated by the use of a type-I trans-
membrane invertase-APP fusion protein as a substrate
(Lu¨thi et al., 2003). In this fusion protein, the invertase
moiety is fused N-terminal to the APP part, which com-
prises a short lumenal stump harboring the b- and the
a-site, the transmembrane domain and the cytosolic
domain. Natural invertase is a secreted enzyme that cat-
alyzes the hydrolysis of sucrose into fructose and glu-
cose and thereby enables yeast to grow on medium with
sucrose as the sole carbon source. The invertase-APP
fusion construct, however, is retained in intracellular
compartments of the secretory pathway via the trans-
membrane domain of APP. Consequently, recombinant
yeast cells, which express invertase-APP instead of the
natural invertase, can not grow on medium with sucrose
as the sole carbon source, unless they express a secre-
tase activity that cleaves within the lumenal APP portion
and thereby liberates the invertase moiety, which is sub-
sequently secreted (Figure 1A). Mkc7p and Yps1p, two
endogenous yeast proteases, were shown to cleave APP
at the a-site (Zhang et al., 1997). Since they both
restored growth of the recombinant yeast cells on
sucrose plates, their genes had to be deleted in order to
demonstrate activity of the engineered BACE1 variant in
yeast cells.
The system described above confers growth to yeast
cells in the presence of active BACE1. This setup is not
ideal for a screening for BACE1 inhibitors, since every
toxic compound would reduce the growth of yeast cells
and thus would produce a false positive signal. To cir-
cumvent this problem, the original readout was reverted
in a way that yeast cells only grow if BACE1 activity is
inhibited. To achieve this, the natural regulation of the
yeast GAL gene network was exploited. A reporter con-
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Figure 1 Yeast assays to monitor BACE1 inhibition: principles
of the negative and the positive growth readout.
(A) Negative growth readout upon BACE1 inhibition: Invertase
activity that is retained in the ER to Golgi compartment via the
transmembrane domain of APP becomes liberated and secreted
upon BACE1 cleavage at the b-site within the APP portion.
Secretion of invertase activity, which hydrolyzes sucrose into
fructose and glucose, is a prerequisite for growth on sucrose
medium. If BACE1 is inhibited, secretion of invertase activity is
prevented and growth on sucrose medium cannot take place.
(B) Positive growth readout upon BACE1 inhibition: BACE1
dependent secretion of invertase activity occurs as described in
A. The medium contains, in addition to sucrose, galactose and
is depleted of histidine. The invertase-dependent hydrolysis of
sucrose produces glucose that dominantly represses the tran-
scription of the HIS3 gene under the control of the GAL1/10
promoter. Since the product of the HIS3 gene is required for
growth in histidine-depleted medium, the yeast cells cannot
grow in the presence of active BACE1. If BACE1 is inhibited,
secretion of invertase activity is prevented and consequently no
glucose is produced. This allows for the activation of the HIS3
gene by galactose and finally for growth on histidine-depleted
medium.
struct, which expresses the HIS3 gene as a growth selec-
tion marker and the lacZ gene as a colorimetric marker
under the control of the divergent GAL1/10 promoter,
was integrated into the genome of yeast cells. The GAL1/
10 promoter is activated by galactose, but dominantly
repressed by glucose. Thus the two reporter genes are
actively transcribed if the yeast cells are grown on galac-
tose medium or on medium containing galactose and
sucrose, as sucrose is inert to the GAL1/10 promoter.
However, if glucose is added to the medium, the tran-
scription of the reporter genes is repressed. If yeast cells
grown on galactose and sucrose secrete invertase, the
sucrose is hydrolyzed into fructose and glucose and the
freshly generated glucose dominantly represses the
expression of the two reporter genes. A combination of
the glucose-repressible reporter gene expression with
the secretase dependent secretion of invertase as
described above couples the activity of the secretase to
a transcriptional readout. In the presence of an active
secretase, the invertase moiety is secreted and the
reporter genes are repressed. Inhibition of the secretase
impedes secretion of the invertase moiety and conse-
quent transcriptional repression (Figure 1B).
Together with the BACE1 variant that was engineered
to be active in yeast, this system allows for a positive
growth selection of samples with impaired BACE1 activ-
ity. In a proof-of-concept study two validated BACE1
inhibitors from Novartis Pharma (Middendorp et al., 2004)
stimulated growth of BACE-expressing cultures in a
dose-dependent manner. Importantly, the two tested
BACE1 inhibitors did not stimulate growth of cultures
expressing the yeast a-secretase Yps1p, thus demon-
strating the specificity of the system. On the other hand,
the non-specific compound MG132 stimulated the
growth rate of both BACE1- and Yps1p-expressing cul-
tures. These results emphasize the importance of having
a control like Yps1p that allows a rapid distinction
between compounds that impair BACE1 function directly
and compounds that interfere with the system in an
unspecific manner.
The main difference of the yeast system compared to
the other cell-based systems described above is the
unique positive growth readout, which prevents the
selection of toxic compounds as false positives. With the
other systems, inhibition of BACE1 is associated with a
decrease of readout signal, which requires monitoring of
cell viability in order to exclude toxic false positives. The
other advantage of the yeast growth readout described
here is provided by the simplicity of the technique with
minimal liquid handling steps and relatively low costs.
Once the yeast suspension has been added to wells con-
taining the test substances, the automated reader simply
measures the cell density after defined time intervals.
The potential of this new technology is demonstrated
by a pilot screening experiment with a chemical com-
pound library of 15 000 small molecules that revealed a
number of compounds that significantly reduced Ab
secretion from HEK 293 APP(Sw) cells.
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Ah peptides, which are believed to be at the origin of Alzheimer’s disease (AD), are produced through the sequential processing of the
transmembrane amyloid precursor protein (APP) by the h- and g-secretase. The identification of small molecules that penetrate the brain and
inhibit these secretases is of great therapeutic potential. Here, we describe a cellular selection system in yeast for the identification of
inhibitors of the human h-secretase BACE-1. Similar to the natural situation in mammalian cells, BACE-1 and its substrate APP are bound to
membranes in secretory pathway compartments. Yeast cells expressing these human proteins have been engineered so as to grow under
selective conditions only upon reduction of BACE-1 activity, thus allowing identification of compounds that, in addition to inhibiting BACE-
1, must permeate cellular membranes and present no cytotoxic effects. Our results show that gradual reduction of BACE-1 expression in the
engineered yeast strain resulted in gradual increase of cell growth rate. Moreover, two validated BACE-1 inhibitors, which have IC50 values
between 7 and 8 AM in mammalian cell assays, stimulated yeast growth in a concentration-dependent manner. This effect was specific for
BACE-1 since these compounds had no effect on yeast cells expressing a different secretase cleaving the APP substrate at the a-site. The
target-specific cellular assay presented here is applicable in high-throughput screens for selecting inhibitors of defined secretases acting on
natural substrates in a membrane-bound protein configuration.
D 2004 Elsevier B.V. All rights reserved.Keywords: Alzheimer; h-Secretase; BACE; h-Secretase inhibitor; Amyloid precursor protein; APP; Cell-based assay
1. Introduction by the so-called h- and g-secretase. An alternative cleavageAlzheimer’s disease (AD) is the most common cause of
senile dementia. The prevalence of AD within the human
population rises considerably with age [1]. By the age of 65
years, about 3% of the human population is affected,
whereas by the age of 85 years the prevalence reaches
almost 50% [2]. A characteristic of the disease is the
presence of extracellular senile plaques, the major compo-
nent of which is the h-amyloid peptide (Ah). The hydro-
phobic, 39–43-amino-acid-long Ah peptide is excised from
the amyloid precursor protein (APP) by sequential cleavage0304-4165/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbagen.2004.05.004
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barberis@esbatech.com (A. Barberis).can occur at the a-site that precludes subsequent h-site
cleavage and, upon proteolysis at the g-site, gives rise to the
shorter, nonpathogenic p3 peptide [3].
Known genetic predispositions for AD mostly affect
genes involved in Ah generation or Ah deposition. Muta-
tions that lead to increased Ah generation are found in the
APP as well as in the g-secretase subunits presenilin 1 (PS1)
and presenilin 2 (PS2). All disease-linked mutations of APP
are clustered around the three cleavage sites (for review, see
Ref. [4]). Transgenic mice expressing mutant human APP
develop many of the neuropathological hallmarks of AD in
an age-dependent manner [5,6]. Since the Ah peptide seems
to play an important role in the pathogenesis of AD, current
therapeutic strategies often focus on inhibition of Ah
deposition and generation [7]. Inhibition of h-secretase
activity represents an attractive option to achieve this goal.
The identification of the aspartic protease BACE-1 as h-
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mice [12–14]. Analysis of these mutated mice revealed no
detectable endogenous Ah production, demonstrating that
BACE-1 is the major h-secretase. Furthermore, these
BACE-1 knockout mice showed no additional phenotype,
thus supporting the notion that h-secretase is potentially an
ideal therapeutic target for treating AD.
Despite major efforts to identify novel h-secretase
inhibitors by applying in vitro high-throughput screening
(HTS) assays with purified soluble BACE-1 fragments and
fluorogenic peptide substrates [15], the best progress
towards efficient BACE-1 inhibition has been achieved
so far by the use of peptidic transition-state mimetic
compounds [10,16–18]. These molecules are in general
highly specific and potent inhibitors of BACE-1 proteo-
lytic activity in biochemical, in vitro assays. However, for
efficient inhibition of h-secretase in cells, their molecular
weight must be reduced and their structure modified so as
to allow for permeation of cellular membranes, the blood–
brain barrier and for activity in the natural cellular envi-
ronment [19]. Some of these crucial issues regarding
biological properties of specific inhibitors could be
addressed already during the early phase of the drug
discovery process by the use of cell-based assays instead
of in vitro assays for the HTS. In addition, there is a need
to establish novel cell-based assays for identifying low
molecular weight inhibitors of secretases that can block
these membrane-bound enzymes at the natural location
within intracellular compartments [20–22]. However,
cell-based HTS assays are generally faced with the prob-
lem that selection signals, as expected if the function of the
defined target is directly affected by specific inhibitors, are
often caused by compounds that interfere with cellular
processes or pathways that are redundant with that of the
target. Indeed, most putative secretase inhibitors identified
by mammalian cell-based screening assays for compounds
reducing the generation of soluble Ah did not specifically
affect h- or g-secretase activity. For example, bafilomycin
A1 or acidotrophic amines impair the production of Ah
through the increase of the pH in intracellular compart-
ments [23–25]; compounds like phorbol 12,13-dibutyrate
or okadaic acid function through protein phosphorylation
[26], and compounds like RO-47-1816/001 simply catalyze
polymerization of Ah, thus reducing the percentage of
soluble peptide [27].
With mammalian cell systems, the distinction between
specific and so-called false-positive signals is especially
challenging due to the high complexity of the redundant
pathways and the laborious genetic manipulation of mam-
malian cells. Nonspecific or indirect effects of compounds
can be much more readily controlled by functionally
reconstituting target activity in yeast, which provides a
heterologous, yet eukaryotic cellular environment. One
major advantage of yeast systems over mammalian cells
is given by the versatile genetic malleability of this
organism, which has made it the model of choice forpioneering research in molecular and cell biology over the
last three decades [28]. Moreover, in contrast to mamma-
lian cells, in which pathway redundancies can often
obscure putative specific effects of compounds on a given
target, a heterologous yeast system permits a clean readout
in a null-background environment for the expression of
many human proteins and the action of inhibitors [29].
Notably, reconstitution of the multimeric g-secretase com-
plex has been achieved recently in yeast [30]. The use of
yeast for cell-based HTS should allow not only for
identification of compounds that can permeate cellular
membranes and be active in an intracellular environment
but also for rapid exclusion of molecules that are not
specific for the chosen target.
We recently published a yeast growth selection system
for detection of secretase activity that cleaves APP in a
cellular context [31]. Yeast cells do not contain endogenous
h- and g-secretase [32]. In this system, a fragment of APP
bearing the h- and the a-site, the transmembrane domain
with the g-site, and the cytosolic tail was fused to the C-
terminus of the yeast enzyme invertase (Suc2p), which is
normally secreted to enable cell growth in the presence of
sucrose as the sole carbon source. Expression of such
invertase–APP fusion protein as a type-I transmembrane
protein in intracellular compartments (ER and Golgi) of
yeast cells lacking endogenous invertase (suc2D) did not
allow growth on sucrose because the invertase moiety was
retained within these compartments. However, co-expres-
sion of an active version of the human h-secretase BACE-1
or of the endogenous a-secretase Yps1p restored cell growth
on selective sucrose plates upon specific cleavage of the
invertase–APP fusion protein and subsequent liberation and
secretion of the invertase moiety [31].
We have exploited the system described above as the
basis for developing a cellular, target-specific HTS system
for identifying secretase inhibitors that are active in eukary-
otic cells. In order to establish a positive selection assay for
inhibitory compounds, and thus automatically eliminate
general cytotoxic compounds, we have reversed the original
cellular readout to confer on yeast cells the ability to grow
only upon inhibition of BACE-1. We show that the system
is sensitive towards various levels of inhibition of BACE-1
and we provide specificity control for rapid exclusion of
false-positive compounds.2. Materials and methods
2.1. Recombinant plasmids
All BACE-1 constructs are carried by ARS1-CEN4
plasmids bearing the URA3 auxotrophic marker and are
derived from the previously described BACEAPP plasmid
[31]. For constructs expressed from the ADH1 full-length
promoter and the ADH1 truncated promoter (deletion up-
stream of the natural SphI site), the BACEAPP XbaI/SalI
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plasmids pMH26 and pMH28, respectively. For the BACE-
1 version expressed from the tetO7 promoter, a BamHI site
was introduced into the XbaI site, and an HpaI site was
introduced into the SalI site of BACEAPP. The resulting
BACEAPP fragment was isolated by HpaI/BamHI digestion
and cloned into pCM189 [33]. Plasmid vectors for the
expression of the invertase–APP fusion protein Suc2-
pAPPSw (referred to as Suc2pAPPKKXX
Sw by Lu¨thi et al.
[31]), which bears the so-called Swedish mutation at the h-
site, and of Yps1p have been described [31]. The integrative
reporter gene plasmid expresses a Gal10p(aa1–47)–His3p
fusion under the control of the GAL10 promoter and the
LacI–LacZ fusion under the control of the divergently
oriented GAL1 promoter.
2.2. Yeast media and transformation
All media were prepared according to Burke et al. [34].
Transformation of yeast cells was performed following the
lithium acetate method [35].
2.3. Yeast strains
The parental strain of Biscre1 is derived from JPY9 and
has been described by Lu¨thi et al. [31] (MATa ura3-52
his3D200 leu2D1 trp1D63 lys2D385 gal4D11 suc2::URA3
yps1::kanMX4 mkc7::HIS3). For constructing Biscre1
(MATa ura3-52 his3D200::lacZ-HIS3 leu2D1 trp1D63
lys2D385 suc2D yps1::kanMX4 mkc7::LYS2), uracil-auxot-
rophy was reconstituted by cultivating the parental strain on
5-fluoro orotic acid (5-FOA). GAL4 was reintroduced by
transformation of a PCR-fragment bearing this gene and
subsequent selection on 2% galactose plates (YPAG). HIS3
was substituted by LYS2 with the use of homologues
recombination. Finally, the lacZ-HIS3 reporter gene plasmid
was integrated at the his3D200 locus. The strain Biscre11 is
a derivative of Biscre1 carrying the deletion of the three
major ABC transporter genes, pdr5D, snq2D, yor1D.
2.4. Western blot analysis
Whole cell extracts from transformed yeast were pre-
pared as described by Burke et al. [34]. Proteins were
separated by SDS PAGE and Western blot analysis was
performed according to standard procedures. A mouse
monoclonal antibody from Sigma (A8717) that recognizes
residues 676–695 of human APP695 was used at a final
concentration of 25 ng/ml to detect expression of BACEAPP
and the CTFh fragment.
2.5. h-Galactosidase assay
Cultures of transformed cells (2 ml) were grown over-
night in 2% glucose  trp  ura medium at 30 jC. These
cells were collected by centrifugation, washed with 5-mlH2O and resuspended in 2-ml assay medium (5% sucrose
2% galactose  trp  ura). Aliquots of these processed pre-
cultures were used to inoculate further 2-ml assay medium
to obtain a starting OD600nm of 0.25. These assay cultures
were grown at 30 jC to OD600nmi1. One hundred micro-
liters of each sample was subjected to h-galactosidase
assays using the method as described by Burke et al. [34].
Activity was normalized to the number of cells assayed. The
experiments were performed in triplicates.
2.6. Growth assays
Growth assays were performed either in conventional test
tubes with manual handling and cell density measurement at
OD600nm, or in microtiter plates for automated handling and
cell density measurement at OD595nm by a microtiter plate
reader. For growth assays in conventional test tubes, 2-ml
pre-cultures were inoculated with transformed cells and
grown overnight in 2% glucose  trp  ura medium at
30 jC. After about 14-h incubation, they were diluted with
2% glucose  trp  ura medium to obtain a cell density
corresponding to OD600nm = 0.25 and further incubated at 30
jC to reach OD600nmi1. These exponentially growing
cultures were washed with 5-ml H2O and resuspended in
2-ml 5% sucrose 2% galactose  his  trp  ura medium
( = growth selection medium). At time zero of the growth
selection experiment, 2-ml cultures of growth selection
medium were inoculated with the processed pre-cultures
to reach a starting OD600nm of 0.05. At the time points
indicated on the relevant figures, OD600nm was determined
in a Shimadzu UV mini-1240 spectrometer. For the OD
measurement, samples were diluted 1:10 in plastic cuvettes
(l = 1 cm). For the experiment with the doxycycline-repress-
ible BACE-1 expression construct, doxycycline (Sigma
D9891) was added as water solution to the growth selection
medium at time zero.
For growth assays in microtiter plates, the experimental
conditions were adjusted in order to optimise them for
automated handling and cell density measurement in a
microtiter plate reader. The differences from the growth
assays described above are the following: The overnight
pre-cultures as well as subsequent dilutions were performed
with the same drop-out medium containing 2% galactose
instead of 2% glucose. The assay cultures had a volume of
150 Al and were incubated in 96-well microtiter plates
(Greiner 655101) without shaking at 30 jC in a 100%
humidity incubator. The BACE-1 expression construct for
these experiments was BACE-ACT1. The BACE-1-specific
inhibitors 1.2. and 4.1. (Novartis Pharma), as well as the
control compound MG132 (Sigma C2211), were dissolved
in DMSO and added to the assay cultures at time zero of the
growth assays; the final DMSO concentration was always
kept at 1%. Prior to light scattering measurement at 595 nm
in a Tecan Genios reader for determining cell density
without diluting the cultures, the microtiter plates were
shaken on a plate shaker for 2 min at 1100 rpm.
Fig. 1. Principle of the system to select BACE-1 inhibitors. Each drawing
depicts a schematic yeast cell that is grown in medium containing sucrose
and galactose. Two cell organelles are indicated: The nucleus containing the
reporter construct with the HIS3 gene and the lacZ gene under the control of
the bidirectional GAL1–10 promoter, and the ER/Golgi compartments
harbouring the membrane-anchored invertase–APP fusion protein. (A)
State of the system in the absence of an active secretase: The invertase
moiety is retained in the ER/Golgi compartments, sucrose remains inert to
the system, and galactose induces transcriptional activation of the reporter
genes. (B) An active BACE-1 enzyme form expressed in the yeast cell
cleaves invertase–APP at the h-site of APP; the invertase moiety is
liberated and secreted to the periplasmic space of the cell, where it
hydrolyses sucrose to generate fructose and glucose. The freshly generated
glucose dominantly represses transcription of the reporter genes. (C)
Addition of a BACE-1 inhibitor restores induction of reporter gene
expression by galactose, thus allowing cell proliferation under selective
conditions.
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3.1. Principle of the growth selection system for the
identification of b-secretase inhibitors
In order to establish a cell-based HTS system for the
positive selection of h-secretase inhibitors, we modified our
previously published system for detection of BACE-1
activity in yeast [31] so as to confer on yeast cells the
ability to grow only upon inhibition or reduction of BACE-1
activity. The readout of the original system, in which
BACE-1 activity correlated with cell growth, is indeed not
suitable for a BACE-1 inhibitor screening system, since
toxic compounds, which are generally not rare in chemical
libraries, would significantly increase the number of false-
positive hits. The new readout exploits the natural regula-
tory network that controls activation and repression of the
divergent GAL1–10 promoters by galactose and glucose,
respectively. In a typical experiment, addition of galactose
to yeast cultures grown on glycerol, a neutral carbon source
with respect to GAL1–10 promoter regulation, induces
expression of the GAL genes at least 1000-fold. If glucose
is added to the galactose-containing media, expression of
the GAL genes is repressed to a level below 1% of that
obtained with galactose alone. This phenomenon is known
as glucose repression [36]. For the BACE-1 inhibitor
screening system, a reporter construct was cloned which
carries the lacZ gene under the control of the GAL1
promoter and the divergently oriented HIS3 gene under
the control of the GAL10 promoter. This reporter construct
was integrated in the yeast genome to generate the strain
Biscre1 (BACE inhibitor screen 1) (see Materials and
methods). Since the natural regulation mode of the
GAL1–10 promoters is preserved in the context of the
new reporter construct, the lacZ and the HIS3 genes of the
strain Biscre1 are fully induced in the presence of galactose
and dominantly repressed upon addition of glucose to the
medium. The product of the HIS3 gene is needed for growth
on histidine-depleted ( his) medium. Consequently, Bis-
cre1 can only grow on  his media that contain galactose
but no glucose. The HIS3 reporter gene of the strain Biscre1,
which lacks the endogenous invertase activity (suc2D), is
also induced when these cells grow in the presence of
sucrose together with galactose (Fig. 1A). However, if
Biscre1 is allowed to secrete the invertase enzyme, glucose
is generated by the hydrolysis of sucrose. The newly
generated glucose dominantly represses the HIS3 gene
expressed from the GAL10 promoter and growth on  his
medium is inhibited (Fig. 1B).
The properties of Biscre1 combined with the BACE-1-
dependent release of invertase from the invertase–APP
fusion protein (Suc2pAPPSw) provide a useful tool to select
for reduced or inhibited BACE-1 activity. Indeed, in the
presence of active BACE-1, the fusion protein Suc2pAPPSw
undergoes cleavage at the h-site; as a consequence, the
invertase moiety is liberated and secreted into the periplasm,where it hydrolyses sucrose into fructose and glucose, the
latter of which represses the HIS3 and the lacZ reporter
genes (Fig. 1B). If BACE-1 is inhibited, either by mutations
or by an inhibiting compound, the invertase moiety remains
anchored to intracellular membranes via the APP domain,
Fig. 2. APP-cleaving secretases cause transcriptional repression of the
reporter genes. (A) h-Galactosidase assay with Biscre1 cells co-transformed
with Suc2pAPPSw (invertase–APP) and an empty vector (column 1),
Yps1p (column 2), mutated Yps1p (column 3), BACE-1 (column 4) or
mutated BACE-1(D93N) (column 5). Each culture was grown in triplicates
in medium containing 5% sucrose and 2% galactose before performing h-
galactosidase assays. The h-galactosidase activity resulting from cultures
harbouring an empty vector (column 1) was arbitrarily set to 1. (B) Growth
assays with aliquots of the same transformed cells described above. Equal
amounts of exponentially growing cultures were used to inoculate 2 ml of
 his 5% sucrose 2% galactose medium. Cell density was determined after
26 h by measuring OD600nm. The assay was performed in quadruplets.
O. Middendorp et al. / Biochimica et Biophysica Acta 1674 (2004) 29–39 33sucrose in the medium is no longer hydrolyzed, and expres-
sion of the HIS3 and the lacZ gene is induced by galactose
(Fig. 1C).
3.2. Expression of active secretases causes transcriptional
repression
In the system outlined above, expression of Suc2-
pAPPSw alone in Biscre1 cells cultivated in the presence
of sucrose and galactose should allow transcription of the
lacZ and HIS3 reporter genes. Conversely, co-expression
of an active and APP-specific secretase together with
Suc2pAPPSw should cause transcriptional repression of
the Biscre1 reporter genes under these conditions. The
GPI-anchored aspartic proteases Yps1p and Mkc7p of
Saccharomyces cerevisiae have been shown to cleave
APP at the a-site [32]. Since the a-site is also present
and accessible in Suc2pAPPSw [31], the endogenous genes
encoding these two yeast a-secretases were deleted in
Biscre1 (yps1D mkc7D). For proof-of-concept experiments
we engaged Yps1p and the BACE-1 construct that has
been shown to be active and specific towards the APPSw
sequence in yeast [31].
Fig. 2 shows that expression of active secretases to-
gether with Suc2pAPPSw in Biscre1 caused repression of
the reporter genes in the presence of 5% sucrose and 2%
galactose in the liquid medium. Transcription of the lacZ
gene was indirectly measured by the h-galactosidase assay.
Co-expression of Suc2pAPPSw with either Yps1p or active
BACE-1 caused a significant reduction of relative h-
galactosidase activity down to 5.7% and 16% of the
activity measured with cells expressing Suc2pAPPSw
alone, respectively (Fig. 2A). Co-expression of Suc2-
pAPPSw with a mutated form of Yps1p lacking its pro-
domain sequence (Fig. 2A, column 3) or with a BACE-1
mutant carrying an amino acid substitution as its active site
(D93N) (Fig. 2A, column 5) resulted in full activation of
the lacZ reporter gene.
The same transformed Biscre1 cells that were used for
the h-galactosidase assay shown in Fig. 2A were examined
for growth in histidine-depleted liquid medium containing
5% sucrose 2% galactose (growth selection medium).
Cultures of differentially transformed Biscre1 cells carry-
ing the five pairs of vector plasmids were inoculated in
quadruplets with equal amounts of exponentially growing
cells from nonselective medium. Cell density was deter-
mined after 26-h incubation by measuring light scattering
at 600 nm (Fig. 2B). Since the results of these growth
selection experiments correlate very closely with the
results of the h-galactosidase assay presented above (com-
pare Fig. 2A with 2B), we conclude that the observed
growth differences reflect different expression levels of the
HIS3 reporter gene. Taken together, the results of both
experiments fulfil the prediction that the presence of active
secretases causes repression of the reporter genes and
subsequent growth inhibition of the Biscre1 strain underselective conditions, while inactivation of the secretases
allows induction of reporter gene expression and cell
proliferation.
3.3. Discrete reduction of BACE-1 expression level results
in discrete increase of cell growth rate
For the proof-of-concept experiments described above,
BACE-1 had been expressed from the strong ACT1 pro-
moter (BACE-ACT1). In order to examine the sensitivity
of the system towards variations of active BACE-1 con-
centrations within the cell, two additional BACE-1 expres-
sion vectors were constructed by substituting the ACT1
Fig. 3. The growth readout is sensitive towards variations of intracellular h-
secretase levels. (A) Growth assay with Biscre1 cells co-transformed with
Suc2pAPPSw and with BACE-1 expressed from different promoters (see
text for detailed information). Equal amounts of exponentially growing
cultures were used to inoculate 2 ml of  his 5% sucrose 2% galactose
medium. Cell densities were monitored after 37 h by measuring OD600nm.
The assays were performed in triplicates. (B) Different intracellular
concentrations of BACE-1 were detected by Western blotting. The signal
corresponding to BACE-1 expressed in yeast cells is indicated by an arrow.
(C) Western blotting analysis of the C-terminal cleavage fragments of
Suc2pAPPSw (CTFh) produced upon cleavage by various BACE-1
concentrations (upper panel). The CTFh band partly overlaps with a much
weaker background band that is also visible in the absence of BACE-1
(empty vector lane). The lower panel shows the results of a Western blotting
analysis of the same whole cell extracts using an antibody directed against
calmodulin (Cmd) as control for general protein concentration.
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full-length ADH1 promoter (BACE-ADH1) and a truncat-
ed version of this ADH1 promoter (BACE-ADH1tr). The
relative strength of these promoters had been previously
tested by comparing h-galactosidase activity from cells
expressing the lacZ gene under the control of one of the
three promoters. In these experiments, the full ADH
promoter gave an activity that was about 40% compared
to that obtained with the ACT1 promoter, whereas the h-
galactosidase activity from the truncated ADH sequence
barely reached 10% of that from the ACT1 promoter (data
not shown). The three different BACE-1 expression vec-
tors were introduced into the Biscre1 strain expressing the
invertase–APP fusion protein Suc2pAPPSw, and their po-
tentially different impact on cell growth under selective
conditions was tested as described above and in Materials
and methods. Fig. 3A shows that cultures of Biscre1 cells
harbouring the BACE-ACT1 construct grew to a maxi-
mum of about 12% of the cell densities reached by Biscre1
cells expressing either the inactive BACE-1 mutant
(BACE(D93N)-ACT1) or no BACE-1 protein (empty
vector). The BACE-ADH1 cultures reached about 50%
of this level, whereas the cultures expressing BACE-1
from the ADH1 truncated promoter grew to about 90%
of the maximum level.
Expression levels of BACE-1 from the three different
promoters were analysed by Western blotting assay (Fig.
3B). The strongest signals on the immunoblot film were
observed as expected in the case of BACE-1 expression
from the strong ACT1 promoter, which also controls
expression of the inactive BACE(D93N) mutant (Fig.
3B). BACE-1 expressed from the full-length ADH1
promoter yielded a less intense signal, whereas expres-
sion from the truncated ADH1 promoter was below
detection limits in this experiment (Fig. 3B). We then
examined whether different intracellular concentrations of
active BACE-1 correlated with differences in the effi-
ciency of cleavage of the Suc2pAPPSw substrate, as we
would expect from the results of the growth assays
shown in Fig. 3A. Aliquots of the cell extracts were
analysed by Western blotting using a monoclonal anti-
body directed against the C-terminus of APP, which
allows detection of the APP cleavage product named
CTFh. Fig. 3C shows that the intensity of the CTFh
signal on the immunoblot film decreased in correlation
with the reduced expression level of active BACE-1
shown in Fig. 3B. The reduced levels of the APP
cleavage product CTFh were inversely proportional to
the levels of cell growth shown in Fig. 3A. As internal
control for the Western blotting assays, we used detection
of the yeast endogenous protein calmodulin (Cmd) by a
specific antibody (Fig. 3C).
These results taken together show that intracellular
concentration of active BACE-1 can be limiting for
cleavage of APP in our cell growth selection system,
and it may be equated with h-secretase activity. Thus,this system is expected to allow detection of gradual
reduction of h-secretase activity by potential BACE-1
inhibitors.
Fig. 4. The growth readout detects modulation of BACE-1 expression by
addition of doxycycline to yeast cells. Biscre1 cells were co-transformed
with Suc2pAPPSw and with BACE-1 expressed from the doxycycline-
repressible tetO7 promoter. The cultures were grown in  his 5% sucrose
2% galactose medium with variable concentrations of doxycycline (as
indicated) at time zero. Cell growth rate was monitored by measuring
OD600nm at the indicated time points. Each point represents the average
measurement of three different cultures.
et Biophysica Acta 1674 (2004) 29–39 353.4. Modulation of BACE-1 expression by variable doses of
doxycycline correlates with distinct changes in cell growth
rate
In the experiments described above, BACE-1 was
expressed at different levels from constitutive promoters
of different strengths. From the results of these experiments,
one can conclude that the described growth selection system
is sensitive towards differences in total BACE-1 activity
within a cell. Nevertheless, because of the constitutive
nature of BACE-1 expression at various levels, these results
do not indicate how the system would perform in a
screening for BACE-1 inhibitors, in which BACE-1 activity
is relatively high at the onset of the experiment (in the
overnight pre-culture) and is then reduced to various extents
upon addition of potential BACE-1 inhibitors to the yeast
cell culture. To address this question, and to test conditions
that would mimic more closely a screening experiment, the
BACE-1 gene construct described above was put under the
control of the doxycycline-repressible promoter tetO7 [33],
which allows modulation of gene expression in yeast by the
addition of different concentrations of doxycycline to the
cell culture.
Biscre1 cells co-transformed with BACE-tetO7 and
Suc2pAPPSw were subjected to growth selection assays as
described above with the only difference that various con-
centrations of doxycycline were added to the yeast cell
culture at time zero (onset of the growth assay). According
to published results [33], the tetO7 promoter is fully active
in the absence of doxycycline and completely silenced in the
presence of 1 Ag/ml doxycycline. In addition to this con-
centration, we used 0.1 and 0.05 Ag/ml doxycycline in order
to obtain different levels of partial repression of the pro-
moter. Fig. 4 shows that growth rate and maximal level of
cell density increased along with increasing doxycycline
concentrations. The maximal OD600nm value measured in
this experiment is very close to the OD600nm values that
were obtained in the presence of inactivated BACE(D93N)-
ACT1 and in the absence of any BACE-1 derivative (see
Fig. 3A). In the absence of doxycycline, yeast cultures grew
to a level that is in the range of that reached upon
constitutive expression of BACE-1 from the ADH1 promot-
er, thus indicating that tetO7 and ADH1 most likely show
similar strength.
These results show that the growth selection system can
discriminate variations of active h-secretase levels caused
by a small compound in a concentration-dependent manner.
3.5. Two validated BACE-1 inhibitors specifically stimulate
growth in a screening assay format
The cellular system described in this paper was designed
with the aim of applying it in screening experiments to
identify specific inhibitors of h-secretase activity. Thus, in
addition to testing the system for selectivity towards mod-
ulation of intracellular expression levels of BACE-1 as
O. Middendorp et al. / Biochimicadescribed above, we wanted to test whether this system
could also be applied for detecting small molecules that
directly inhibit BACE-1 activity by binding to this enzyme.
To this purpose, we challenged the growth selection system
with the validated BACE-1-specific inhibitors 1.2. and 4.1.
of Novartis Pharma. The in vitro IC50 and the cell culture
IC50 values of compound 1.2. are 16 nM and 8 AM,
respectively. The corresponding values for compound 4.1.
are 140 nM and 7 AM, respectively. A more detailed
characterisation of these compounds will be published
elsewhere (U.N. and P.P., manuscript in preparation).
For these experiments, we used the yeast strain Biscre11,
a derivative of Biscre1 in which the genes for the three
major ATP-binding cassette (ABC) transporters Snq2p,
Pdr5p and Yor1p have been deleted. These ABC trans-
porters, also known as efflux pumps, are important compo-
nents of the yeast pleiotropic drug resistance network, which
counteracts accumulation of unwanted or potentially toxic
compounds within the yeast cell [37]. For efficiently screen-
ing small molecule libraries in yeast with manageable
compound concentrations, it is much preferable to use
strains lacking the major ABC transporters [38]. Biscre11
cells co-expressing either BACE-1 and Suc2pAPPSw or
Yps1p and Suc2pAPPSw were incubated with various con-
centrations of the BACE-1 inhibitors 1.2. and 4.1. in micro-
titer plates and cultivated under selective conditions for 24
h as described in Materials and methods. Fig. 5A shows that
increasing concentrations of the BACE-1 inhibitors 1.2. and
4.1. correlated with increasing growth of the BACE-1-
expressing Biscre11 cultures. At the highest tested concen-
tration, growth stimulation was about 30% for compound
Fig. 5. The validated BACE-1 inhibitors 1.2. and 4.1. stimulate growth in
a specific manner under selective conditions. (A) Increasing concen-
trations of compound 1.2. (upper panel) and 4.1. (lower panel)
increasingly stimulate cell growth. 150 Al cultures of Biscre11 cells
expressing Suc2pAPPSw and BACE-1, or Suc2pAPPSw and Yps1p, were
grown either in the absence (0) or in the presence of increasing
concentrations of compounds 1.2. and 4.1. (indicated in micromolar). The
histidine-lacking medium contained 1% DMSO 5% sucrose 2% galactose.
The experiment was performed in quadruplets. Growth was monitored
with a microtiter plate reader at OD595nm after 24 h. (B) Effect of 10 AM
MG132 on growth of Biscre11 cells expressing Suc2pAPPSw and BACE-
1, or Suc2pAPPSw and Yps1p. The applied growth conditions were
identical as described above.
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rescue effect in the presence of BACE-1, the growth of
cultures expressing the yeast a-secretase Yps1p could not be
rescued by neither of the two compounds at the tested
concentrations. The slight differences in cell densities be-
tween BACE-1- and Yps1p-expressing cultures observed in
the absence of these inhibitors are consistent with the results
of previous experiments under different conditions (see, e.g.
Fig. 2), and are most likely the consequence of differences
in substrate cleavage efficiency by the two secretases and
subsequent invertase secretion [31]. These results show that
the BACE-1 inhibitors 1.2. and 4.1. are able to rescue
growth of engineered Biscre11 cells in a concentration-
dependent manner that is specific for cells expressing
BACE-1.
To further control our growth selection system and to
establish optimal conditions for application in screening
assays, we tested the proteasome inhibitor MG132, which
causes reduction of Ah secretion from mammalian cells by
preventing h-secretase cleavage in an indirect manner, most
likely by impeding progression of APP through the secre-
tory pathway [39]. Addition of 10 AM MG132 to Biscre11
cultures co-expressing either BACE-1 and Suc2pAPPSw or
Yps1p and Suc2pAPPSw resulted in both cases in significant
growth stimulation when compared to control cultures
incubated with DMSO alone (Fig. 5B). Since the same
effect was observed in the absence of BACE-1 when natural
invertase (Suc2p) was expressed instead of Suc2pAPPSw
(data not shown), we conclude that, similarly to what is
believed to happen in mammalian cells, MG132 probably
acts by generally inhibiting progression of proteins through
the secretory pathway. These results, taken together, em-
phasize the importance of having a specificity control for
compounds identified by cellular screenings, a condition
that can be readily and inexpensively achieved with the
genetically malleable yeast cells.
In summary, the cellular growth selection system pre-
sented here allows detection of the effect of the validated
BACE-1 inhibitors 1.2. and 4.1. in an efficient manner.
Moreover, components of the system can be readily changed
for establishing important specificity controls for the assay,
as it has been shown with the use of the Yps1p secretase and
the nonspecific compound MG132. In a screening for novel
inhibitors of BACE-1, compounds that could block the
residual endogenous a-secretase activities in yps1D mkc7D
strains (which have been reported to be responsible for
about 14% APP cleavage [32]) might also cause growth
stimulation in the presence of BACE-1. If such compounds
would not inhibit the control a-secretase Yps1p, and if they
would show their effect only in the presence of BACE-1 but
not when Yps1p is expressed, they could appear as BACE-
1-specific inhibitors in our system. Since characterization of
so-called primary hits selected by a compound library screen
would in any case require further experiments like test of
activity in mammalian cells and protein binding assays, such
expectedly low number of yeast residual secretase inhibitors
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discovery process.4. Discussion
The present work describes a readily applicable cellular
screening system for the identification of in vivo h-secretase
inhibitors. The system, which is based on positive growth
selection, combines the previously described BACE-1-de-
pendent release of the yeast enzyme invertase [31] with the
properties of the newly engineered strain named Biscre1.
Biscre1 harbours the reporter genes lacZ and HIS3 under the
control of the GAL1–10 promoter, which is repressed in the
presence of active BACE-1 (see Fig. 1). Reduction of
BACE-1 expression or inhibition of its activity by a specific
inhibitor relieves the reporter genes from repression and
allows transcriptional activation. Reporter gene expression
endows these cells with readily detectable properties such as
the ability to grow under selective conditions and to be
sorted by colorimetric assays, thus providing a means for a
cell-based HTS of compound libraries.
We have performed proof-of-concept experiments to
show that changes in the expression level of BACE-1
inversely correlate with changes in the growth rate of the
engineered yeast cells. Results supporting such correlation
have been reproducibly obtained both in the case of consti-
tutive expression of different levels of BACE-1 and in the
case of reduction of BACE-1 expression by the small
molecule doxycycline (see Figs. 3 and 4). The latter
experimental setup more closely mimics the situation in
which a BACE-1 inhibitor added to the yeast culture can be
identified because it reduces activity of h-secretase to a
given percentage of the originally fully active enzyme
population.
Although the results of such BACE-1 expression experi-
ments provided good evidence that the system should allow
detection of a BACE-1 inhibitor, the final proof came by
testing the effect of the validated BACE-1 inhibitors 1.2.
and 4.1. on cell growth stimulation in the selection system.
The small molecules 1.2. and 4.1. can indeed stimulate
growth of yeast cells expressing BACE-1 in a concentra-
tion-dependent manner (see Fig. 5A). It is noteworthy that,
although the in vitro IC50 values of the compounds 1.2. and
4.1. differ by about a factor of 10 (16 and 140 nM), the
levels of growth stimulation exerted by increasing concen-
trations of these two compounds in our yeast system are
comparable between each other. Such similar behaviour in
the yeast selection system is in better agreement with the
properties of the compounds observed in cell culture experi-
ments, in which these compounds showed similar IC50
values for inhibition of BACE-1 in vivo (U.N. and P.P.,
unpublished results). Importantly, neither compound 1.2.
nor compound 4.1. did rescue growth of yeast cultures
expressing Yps1p, whereas 10 AM of the peptide aldehyde
MG132 rescued both Yps1p and BACE-1-expressing cul-tures. These results demonstrate that our system is able to
detect BACE-1 inhibition and, furthermore, that false-pos-
itive compounds such as MG132, which would be detected
in a screening assay, can be rapidly excluded by use of a
control secretase like Yps1p. The proteasome inhibitor
MG132 has been known for a long time to reduce Ah
secretion from mammalian cells [40], but the precise mode
of action remains unclear. To our knowledge, MG132 has
not been shown to directly inhibit BACE-1 activity towards
APP. It has been suggested that MG132 inhibits g-secretase
activity [40]; other results have rather indicated that this
effect of MG132 might be due to a direct or indirect
impairment of APP progression through the secretory path-
way [39]. Our results support the second explanation.
Indeed, in addition to the fact that yeast cells do not exhibit
any g-secretase activity, MG132 has an effect on the readout
of our invertase secretion system even when plain invertase
is expressed in the absence of BACE-1.
Our yeast selection system combines advantages of in
vitro assays with those of mammalian cellular systems. Cell-
based assays allow early selection of compounds that show
membrane permeability and the ability to function in the
reactive environment of a living cell. Addressing these
issues already in the primary screening might crucially
accelerate the drug discovery process and thus lower the
costs. Moreover, the activity of the target protein and its
substrate, as well as the readout to monitor the effect of
compounds, are examined in a cellular context that should
recapitulate more closely than in vitro assays the natural
physiological state in which the specific compound should
ultimately function. In vitro assays to identify BACE-1
inhibitors are usually established with a soluble fragment
of this enzyme together with a short peptide substrate. A
recent publication described a novel in vitro assay with a
membrane-bound form of BACE-1 incubated with the short
peptide substrate. The authors of that paper observed no
significant difference between their novel assay and the
classical one with soluble BACE-1 regarding inhibition by
two peptidomimetic competitive inhibitors [41]. However,
while these results revealed that membrane anchoring was
not relevant for BACE-1 activity (and inhibition) on the
short peptide substrate, they did not address the potential
importance of presenting the natural h-secretase substrate
APP as transmembrane protein. It is plausible that there are
small molecule inhibitors of h-secretase that efficiently
function only on the cleavage of the natural substrate, for
example by causing allosteric changes that interfere with the
BACE-APP interaction.
The yeast cell growth selection system described here
overcomes one major disadvantage of conventional screen-
ing assays with mammalian cells, which is the difficulty to
distinguish direct inhibitory effects on the defined target (h-
secretase) from other effects on redundant pathways, cell
metabolism and cell viability [42]. The versatile genetic
malleability of yeast has allowed us to readily address this
problem by engineering cells in which inhibition of human
O. Middendorp et al. / Biochimica et Biophysica Acta 1674 (2004) 29–3938BACE-1 is associated with cell growth, and by including
simple control tests such as those with alternative APP-
cleaving enzyme (see Fig. 5). These controls allow for rapid
exclusion of molecules that are not specific for the chosen
target. Thus, similar to in vitro assays, the heterologous
yeast system allows for a clean readout for the expression of
human BACE-1 and the effects of inhibitors. At the same
time, the use of yeast for cell-based HTS also allows
selection of compounds that can permeate cellular mem-
branes and that are active in the intracellular environment
without causing toxicity.
In summary, we have developed a novel cellular system
for the identification of BACE-1 inhibitors, which com-
prises a convenient method for rapid exclusion of so-called
false-positive compounds and allows concomitant selection
for cell permeability and against general cytotoxicity. We
recently performed a screening experiment with a chemical
compound library of 15,000 small molecules. This screen-
ing assay delivered 13 compounds that stimulated growth of
yeast cells in a BACE-1-dependent manner. Initial charac-
terization of these compounds revealed significant inhibition
of BACE-1 activity in vitro by some of the molecules and
reduction of Ah secretion from HEK 293 APP(Sw) cells.
Results of these experiments will be published elsewhere
after further analysis of the identified compounds and
optimised derivatives of them.Acknowledgements
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3.2. Identification of potential small molecule inhibitors of the β-
secretase 
3.2.1. Results 
Primary screening for BACE1 inhibitors 
The “Yeast growth selection system for the identification of cell-active inhibitors of β-
secretase” (Middendorp et al., 2004) as described in part 3.1. of this thesis was applied 
for the screening of a chemical compound collection of 15’000 small molecules. 
The yeast strain that was used for this screening is a Biscre1 derivative (Biscre11), 
which was genetically modified with the aim to increase the intracellular concentration of 
the library compounds during the screening. It is known that intracellular accumulation of 
small molecules is generally much more limited in yeast cells compared to cultured 
mammalian cells. This is primarly due to the very efficient yeast pleiotropic drug 
resistance network, which pumps potentially toxic substances out of the cell, and, to some 
extent also, due to a different permeability of yeast cell membranes compared to 
mammalian cell membranes. A crucial difference between mammalian and yeast cell 
membranes is that cholesterol is replaced by ergosterol. A strain, which is deleted for the 
ERG6 gene, the product of which is involved in the ergosterol synthesis, displays an 
increased rate of passive diffusion through the cell membrane (Emter et al., 2002). Our 
screening strain Biscre11 carries a wildtype allele for ERG6 (We were able to delete 
ERG6, but any further attempts to genetically manipulate the strain failed, despite the 
usage of a special “erg6∆ transformation protocol” as described by Gaber et al. (Gaber et 
al., 1989).), but is deleted for the genes PDR5, SNQ2 and YOR1, which encode 
components of the yeast pleiotropic drug resistance network. A combination of pdr5∆, 
snq2∆ and yor1∆ produces a strain, which is sensitive towards a broad spectrum of 
different compound classes (Kolaczkowski et al., 1998). For the screening we used 
Biscre11 cells that were pre-transformed with plasmids encoding BACE1 (BACE-ACT1) 
and the invertase-APP (Suc2pAPPSw) fusion protein (herein after referred to as BACE 
strain). 
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The screening was performed in a 96 well plate format. Beside 80 wells containing 
different test substances dissolved in dimethyl sulfoxide (DMSO), on each plate there 
were eight wells containing the negative control (DMSO) and four wells containing the 
positive control being MG132. Addition of 150 µl of BACE strain suspension, 
resuspended in histidine-depleted medium with 5% sucrose and 2% galactose (growth 
selection medium), resulted in a final DMSO concentration of 1% in every well. The final 
concentration of the test substances was approximately 50 µM; the final concentration of 
MG132 was 10 µM, which stimulates the growth of BACE cultures by about a factor of 
two (see part 3.1. figure 5c). The variability of the signals for the negative and the 
positive controls as well as the width of the signal window is taken into account by the 
so-called Z’ factor (see materials and methods for formula), which is calculated for each 
plate. The Z’ factor is a widely accepted indicator for the statistical performance of a 
screening assay (Janzen, 2002). It is a dimensionless parameter that ranges from 1 to 
values < 0. If the Z’ factor is < 0, the signal population of the positive control overlaps 
with the signal population of the negative control (a Z’ factor of 1 would indicate infinite 
separation of the two populations). For a cellular screening, a Z’ factor > 0.3 is 
acceptable. This was achieve with the BACE1 inhibitor screening in yeast, for which the 
Z’ factors usually ranged from 0.3 to 0.8. 
The chemical library was screened twice with the BACE strain. The cell densities were 
determined after 20, 26 and 32 hours incubation by measuring light scattering at 595 nm 
(OD595 nm). The relative effects of the test substances on cell growth were calculated in 
relation to the growth of the negative control. A primary hit was defined as a compound, 
which stimulated growth of BACE cultures repeatedly ≥ 5% at one (or several) given 
time point(s). This yielded 662 primary hits. (For an overview of the screening and the 
further proceedings see figure 1.) 
BACE dependence of primary hits 
Interference with BACE1 function is one of many possibilities for a compound to 
stimulate growth of BACE cultures. Since BACE activity is coupled to the growth 
readout via secretion of invertase activity and the transcriptional regulation of the GAL1-
10 promoter (see part 3.1. figures 1 and 2), every compound that interferes with the 
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function of invertase (secretion or enzymatic activity) or with the glucose repression of 
the GAL1-10 promoter produces a false positive signal. These kinds of false positive 
compounds can be excluded by testing them in a strain that secretes invertase activity in a 
BACE1-independent way. This can be achieved by replacing BACE1 by another 
secretase, e.g. Yps1p that liberates the invertase moiety from the invertase-APP fusion 
protein by cleaving at the α-site, or by using a strain, which constitutively secretes 
natural invertase. If a compound stimulates not only the growth of the BACE strain, but 
also the growth of one of these two control strains, its mode of action is obviously not 
BACE-dependent.  
Three growth assays were performed to confirm the growth stimulation observed in the 
screening and to investigate the BACE dependence of the 662 primary hits. The growth 
assays were performed twice with the BACE strain (reproduction of the screening results) 
and once with Biscre11 cells transformed with a plasmid encoding natural invertase 
(herein after referred to as invertase strain; BACE dependence test). For these growth 
assays each compound was tested at concentrations of approximately 50 µM, 25 µM and 
12.5 µM. Cell densities were determined after 20, 26 and 32 hours incubation. This 
produces a dataset of nine measure points per compound and growth assay. A primary hit 
was considered as BACE-dependent if the following requirements were met at one 
measure point for all growth assays: The growth stimulation of the BACE strain must be 
at least 5% in both growth assays, whereas the growth stimulation of the invertase strain 
must be less than 0%. These criteria were met by 28 compounds. However, since a 
computer produced this list by considering isolated measuring points, the datasets of 
these 28 compounds were manually reviewed to get a more complete picture of the 
performance of the compounds. After this procedure there were 14 compounds left, 
which showed concentration-dependent growth stimulation of the BACE strain, but not 
of the invertase strain. 
For the final test in yeast, the 14 compounds were reordered and freshly dissolve in 
DMSO. The setup of the experiment was the same as for the BACE dependence test of 
the 662 primary hits except that the compounds were tested additionally in Biscre11 cells 
transformed with plasmids encoding Yps1p and the invertase-APP fusion protein (herein 
after referred to as Yps1p strain). As shown in table 1, after this test there were eight 
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compounds still considered as BACE-dependent, four were rejected and two were 
proceeded because of convincing previous results although in this test they were no more 
BACE-dependent. 
Analysis of candidate compounds by measuring Aβ secretion from HEK 293 cells 
The final goal of therapeutic BACE1 inhibitors would be to reduce the deposition of 
Aβ peptide in the brain. It is therefore an early and important milestone for candidate 
compounds to reduce Aβ secretion in cell cultures. To investigate this issue, HEK 293 
cells overexpressing the Swedish mutation of APP (Citron et al., 1992) were incubated 
with 20 µM of the test candidates for two days before the secretion of Aβ40 peptide was 
quantified by the use of a sandwich ELISA. In parallel to the Aβ ELISAs there were also 
XTT reduction assays performed to monitor cell viability. The results normalized to the 
negative control (0.1% DMSO) are shown in figure 2A. The γ-secretase inhibitors VII 
(Durkin et al., 1999) and IX (Dovey et al., 2001), which served as positive controls, were 
added at concentrations of 5 µM and 0.1 µM causing a reduction of Aβ40 secretion of 
about 40% and 80%, respectively. None of the ten tested compounds exhibited significant 
toxicity to the cells and six of them caused a significant reduction of Aβ40 peptide in the 
conditioned cell culture medium. Five compounds caused a comparable reduction of 
about 20%. The biggest reduction was observed for the compound 102H6, for which a 
dose dependency is shown in figure 2B. However, the initially observed reduction by 20 
µM 102H6 was not reproduced to the extent of 60%. For the dose dependence 
experiment the maximal reduction was 40% at a concentration of 25 µM. 
In vitro analysis of putative BACE1 inhibitors 
In order to confirm the mode of action of the compounds that were selected by the yeast 
screening system they were tested with an in vitro assay for inhibition of BACE1. This is 
necessary, since both, the yeast readout and the measurement of secreted Aβ from HEK 
293 cells involve the secretory pathway, which leaves the possibility that selected 
compounds do not act on BACE1, but interfere with the secretory pathway instead. 
In vitro BACE1 activity was assessed by the use of soluble BACE1 ectodomain and 
two different fluorescence resonance energy transfer (FRET) substrates. The two 
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substrates referred to as FS-IV and FS-VI essentially differ in their fluorescence 
donor:acceptor pairs and the adjacent amino acids, whereas the p4-p4’ residues are 
identical. For the cleavage of FS-IV there was substantial inhibition observed by some of 
the compounds (see table 2), but cleavage of FS-VI was never affected. Autofluorescence 
or quenching effects of the test compounds can be excluded to explain these differences, 
since this was tested before the measurements. Furthermore, the positive control, the 
peptidic transition state mimetic inhibitor P10-P4’StatVal revealed IC50 values of 80 nM 
with both substrates, which is in the range of the published IC50 values of 30 nM as 
determined in the original publication (Sinha et al., 1999) and of 200 nM as determined 
by Grüninger-Leitch et al. (Grüninger-Leitch et al., 2002). The same was true for a 
second positive control, the peptidic transition state mimetic inhibitor OM99-2 (Ghosh et 
al., 2000), for which we also observed comparable inhibition with both substrates. 
3.2.2. Discussion 
The screening of 15’000 small molecules by our novel yeast growth selection assay 
revealed 10 compounds, which stimulated the growth of yeast cells in a BACE-dependent 
manner. Six of these compounds caused a significant reduction of Aβ secretion from 
HEK 293 APP (Sw) cells and five compounds significantly inhibited BACE1 activity in 
an isolated enzyme assay. An overview of the performance of these 10 compounds in the 
different systems is shown in table 3. Four compounds are active in all three systems, two 
only in yeast and cell culture, one in yeast and in vitro, and three compounds are only 
active in yeast. There is no obvious correlation between the performance of the 
compounds in yeast and their performance in the other systems. The two compounds 
performing best in yeast only show additional activity in either the cell culture assay 
(101C3) or the in vitro assay (77H7) and the compounds performing next best in yeast 
(48E8 and 90C10), both do not show any activity in another system than yeast. The 
compounds being active in all three systems (36D10, 102H6, 103B3 and 128D2) show a 
low to medium performance in yeast. We assume that Biscre11 cells, which are deficient 
for the drug efflux pumps Pdr5p, Snq2p and Yor1p display an increased sensitivity 
towards a broad spectrum of compounds compared to wildtype yeast cells, but are still 
less sensitive than cultured mammalian cells. This could explain, how a compound 
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producing a relatively small growth stimulation in yeast already provokes an effect in 
mammalian cells, but not why a compound producing a high and BACE-dependent signal 
in yeast, does not respond in the other systems. This lack of clear correlation between the 
yeast system and the other systems is not necessarily a drawback for the yeast selection 
as a tool for primary screenings, since its good statistical performance allows for setting a 
low threshold of 5% growth stimulation, which should not be a bottleneck for true 
positives. However, due to the lack of correlation and the artificial character of the yeast 
system, it is not suitable as a tool for hit validation or to rank candidates of a hit 
expansion. 
In part 3.1. it was stated that compounds identified by the yeast system would be pre-
selected for membrane-permeability and against general toxicity. This seems to hold true, 
since none of the compounds tested in cell culture revealed significant toxicity and six 
out of ten caused a significant reduction of Aβ secretion. The mode of action of the six 
compounds affecting Aβ secretion, however, remains to be elucidated. Since both, the 
yeast readout, as well as the quantification of Aβ peptide in the conditioned medium, 
involve the secretory pathway, a compound interfering with the secretory pathway of 
yeast and of mammalian cells would produce a positive signal with both readouts. 
Although the compounds seem to be BACE-dependent in yeast as determined by the use 
of constitutively secreted invertase and Yps1p-dependent secretion of invertase it is still 
important to demonstrate their mode of action in another system than the one with which 
they were discovered. For this purpose we performed in vitro assays using two different 
fluorescence resonance energy transfer (FRET) assays. The results from these 
experiments however were not conclusive, since the significant and reproducible 
inhibition by five compounds as determined with the first assay substrate could never be 
reproduced with the second assay, whereas the positive controls worked well with both 
substrates. Up to the present we could not track down the factors, which are responsible 
for the observed differences and we cannot yet be sure, whether the identified compounds 
are bona fide BACE1 inhibitors. Further investigations will be necessary to answer this 
question. There are alternative possibilities to determine the mode of action of putative 
BACE1 inhibitors. Beside alternative in vitro readouts involving detection of cleavage 
products by high performance liquid chromatography, mass spectrometry or ELISA, the 
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extent of β-site cleavage could also be assessed in vivo. This could be achieved by 
quantifying the N-terminal cleavage products of APP sAPPα and sAPPβ as described for 
example by Steinhilb et al. (Steinhilb et al., 2000). 
A conclusive evaluation of the yeast growth selection is not yet possible, since i) it is 
not yet clear, whether it identified bona fide BACE1 inhibitors, ii) the number of 
screened compounds is relatively small and iii) a direct comparison with other screening 
systems is not possible, since this particular library was only screened with the yeast 
system. As discussed in previous sections of this thesis, BACE1 is a potentially ideal 
drug target from a biological point of view, and consequently there is a huge interest to 
find potent inhibitors. However, from a pharmacological point of view, BACE1 proofed 
to be a challenging target (see also part 2.4). Despite the effort of many academic groups 
and several big pharma companies to identify potent small molecule inhibitors of 
BACE1, there are no publications describing successful screenings for BACE1 inhibitors. 
Since already the screening of our small library revealed a considerable number of 
promising candidates, we believe that it would be worth applying the yeast selection 
system to screen a larger library. 
3.2.3. Materials and methods 
Yeast media and transformation 
All media were prepared according to Burke et al. (Burke et al., 2000). Growth 
selection media: 5% sucrose 2% galactose –his –ura –trp; the sucrose was dissolved in 
2% galactose –his –ura –trp liquid medium and sterile filtered immediately before use. 
Transformation of yeast cells was performed following the lithium acetate method (Gietz 
et al., 1992). 
Yeast strains and plasmids 
The yeast strain Biscre11 is a derivative of Biscre1, which is described in materials and 
methods of part 3.1.. To generate Biscre11 the genes PDR5, SNQ2 and YOR1 were 
sequentially deleted using in vivo site-directed mutagenesis as described by Storici et al. 
and referred to as “delitto perfetto” (Storici et al., 2001). The expression plasmids used 
for this study were the same as described in part 3.1., with the addition of the plasmid 
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encoding for natural invertase (Suc2p). The ORF of SUC2 was subcloned (BstBI → 
blunted/SalI) from the plasmid encoding the full-length version expressed from the ACT1 
promoter as described by Lüthi et al. (Lüthi et al., 2003) into the multiple cloning site 
(StuI/SalI) of pMH28 (described by Urech et al. (Urech et al., 2003)), which drives 
expression from a truncated ADH1 promoter. 
The chemical library 
The chemical library was designed so as to maximize structural diversity among the 
molecules. Furthermore the molecular weight (MW) of the compounds was kept below 
500 g/mol. The resulting selection, which revealed a high score with the Lipinski rules 
(MW ≤ 500 g/mol, logP ≤ 5, H-acceptors ≤ 10, H-donors ≤ 5, rotable bonds ≤ 8), was 
ordered at ChemDiv and was delivered as white and colored powders in 96 deep well 
plates. 80 wells of each plate were filled with approximately 1 mg of different 
compounds, which were dissolved in DMSO to an approximate concentration of 5 mM 
generating the so-called “grandmother plates”. 100 µl aliquots of the “grandmother 
plates” were transferred to V-shaped polypropylene 96 well plates (Greiner bio-one 
651201) to generate the so-called “mother plates”. The wells A1-H1 of the mother plates 
were filled with 100 µl of DMSO, the wells A12-H12 were empty. The grandmother 
plates were stored at –20°C, the mother plates at 4°C. 
The screening procedure 
The library was subdivided into 5 batches of 38 plates (batch 5 contained only 36 
plates). The screening capacity was one batch in 2 days, which gives a screening 
throughput of 1520 compounds per day. To screen one batch, a 50 ml preculture was 
inoculated with Biscre11 cells transformed with BACE-ACT1 and Suc2pAPPSw and 
grown overnight in 2% galactose –trp –ura medium at 30°C. After about 14 hours 
incubation, it was diluted with 2% galactose –trp –ura medium to obtain a cell density 
corresponding to OD600 nm = 0.25 and further incubated at 30°C to reach OD600 nm ≅ 1 
(determined for a 1/10 dilution in a Shimadzu UV mini-1240 spectrometer, l = 1 cm). 
This exponentially growing culture was washed with 50 ml H2O and resuspended in 50 
ml growth selection medium before it was used to inoculate 900 ml of growth selection 
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medium to reach a starting OD600 nm of 0.05. The screening plates were prepared as 
follows: 1.5 µl aliquots from the mother plates were replica plated into flat bottom 
polystyrene 96 well plates (Greiner bio-one 656101) by the use of a Tomtec 96 needle 
pipeting robot. The positive control, 1.5 µl of 1 mM MG132 was added by hand to the 
wells C12-F12. The following steps were performed in a fully automated manner by a 
Tecan robot: 150 µl of yeast suspension were added to each well of the screening plates, 
which were shaken 4 times for 10 seconds with alternating directions at 1100 rpm before 
the OD595 nm was measured (= blank values, t = 0) in a Tecan Genios reader. After 20, 26 
and 32 hours incubation without shaking at 30°C 100% humidity, the cell densities were 
determined as described for measuring the blank value. For the evaluation, the blank 
value was subtracted from the values obtained after 20, 26 and 32 hours. The statistical 
performances of the screening plates were assessed by calculating the Z’ factor: 
Z’ = 1-3 x (SDpositive control + SDnegative control)/AVpositive control – AVnegative control  
(SD: Standard deviation; AV: Average) 
For the BACE dependency tests in yeast, there were new mother plates composed by 
picking and diluting the selected compounds from the original mother plates, or, for the 
second round of BACE dependency test, with the reordered and freshly dissolved 
compounds. Otherwise, the growth assays were performed as described above.  
Cell culture, XTT reduction assay and Aβ ELISA 
HEK 293 cells overexpressing the Swedish mutation of APP (Citron et al., 1992) (a 
kink gift from Christian Haass) were grown in 10 cm tissue culture dishes with 10 ml 
Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% FCS and 200 
µg/ml G418 (herein after referred to as cell culture medium) to near-confluence before 
they were trypsinized. After washing the cells with cell culture medium lacking phenol 
red, the cell density of the cell suspension was determined with the Neubaur counter 
chamber. After dilution with cell culture medium lacking phenol red, the cells were 
seeded into 96 well plates containing the test substances to reach 50’000 cells per well 
resuspended in 150 µl cell culture medium lacking phenol red. The final concentration of 
the test substances was 20 µM, the final DMSO concentration was 0.1%. Every 
compound was tested in triplicates. After 2 days of incubation at 37°C, 5% CO2 and 
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100% humidity 30 µl of conditioned medium were removed. The residual 120 µl were 
subjected to the XTT reduction assay: 40 µl of XTT/phenazine methosulfate (PMS) 
solution (1:20 dilution of 500 µM PMS in 1 mg/ml XTT dissolved in cell culture medium 
lacking phenol red) were added to each well, and after 45 minutes incubation at 37°C, 5% 
CO2 and 100% humidity, the OD450 nm was determined in a microtiter plate reader. For 
the Aβ40 ELISA, a commercially available kit (hAmyloid β40 ELISA (HS) from The 
Genetics Company) was used. The conditioned medium was diluted 1:50 in sample 
dilution buffer and the samples were proceeded according to the manual.  
FRET assays 
All FRET assays were performed in triplicates in 384 well plates in an assay volume of 
50 µl. The reaction was performed in 100 mM NaOAc pH 4.5 with 20 nM recombinant 
human BACE1 ectodomain (R&D systems, 931-AS-050) at a substrate concentration of 5 
µM and a final DMSO concentration of 2.5%. The test substances were pre-incubated at 
indicated concentrations with the enzyme for 30 minutes at 37°C or 30°C before addition 
of the substrate and starting the measurement in a microtiter plate reader (Tecan Genios). 
For experiments using FS-IV (H-Arg-Glu(EDANS)Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-
Lys(DABCYL) Arg-OH; Calbiochem 565758) as a substrate the measurements were 
performed in white 384 well plates (Nunc 3911932) at 37°C, at an excitation wavelength 
of 360 nm and an emission wavelength of 485 nm. For experiments using FS-VI (H-
Lys(DABSYL)-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Arg-Gin-(lucifer yellow); 
Calbiochem 565781) as a substrate the measurements were performed in black 384 well 
plates (Corning #3654) at 30°C, at an excitation wavelength of 430 nm and an emission 
wavelength of 520 nm. The intial velocities were calculated using the values obtained 
between the 2nd and the 10th minute of the reaction. Enzymatic activity in the presence of 
a test compound was calculated as percentage of the initial velocity compared to initial 
velocity of the negative control, which was set to 100%. The BACE1 inhibitors OM99-2 
and P10-P4’StatVal were acquired by purchase from Bachem (H5108) and Calbiochem 
(171601), respectively. 
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3.2.4. Figures and tables 
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Figure 1 Overview of the selection of putative BACE1 inhibitors
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Figure 1 Overview of the selection of putative BACE1 inhibitors. (1) 15’000 compounds 
were screened twice with the BACE strain (Biscre11 transformed with BACE-ACT1 and 
Suc2pAPPSw). 662 compounds that stimulated growth repeatedly >5% after 20, 26 or 32 
hours incubation were selected and subjected to (2) the BACE dependency test: 28 
compounds stimulating the growth of the BACE strain twice >5% and the growth of the 
invertase strain (Biscre11 transformed with a plasmid encoding natural invertase) <0% at 
a concentration of 12.5 µM, 25 µM or 50 µM after 20, 26 or 32 hours incubation were 
selected as being BACE-dependent. (3) The complete datasets obtained for the 28 
compounds during the BACE dependency test were manually reviewed. After this 
procedure there were 14 compounds remaining, which were reordered and dissolved in 
DMSO immediately before they were subjected to the final test in yeast (4). The freshly 
dissolved compounds were tested with the BACE strain, the invertase strain and the 
Yps1p strain (Biscre11 transformed with Suc2pAPPSw and a plasmid encoding Yps1p). 
This test confirmed BACE dependency of 10 compounds, which were subjected to cell 
culture experiments with HEK 293 cells overexpressing the Swedish mutation of APP 
(5). Among these 10 compounds there were 6, which significantly reduced the amount of 
Aβ peptide in the conditioned medium. 
 51


*

+
"
"
"*
"

)
!


,
)



 -




































*

+
"
"
"*

















)
!


,
)
  
 
Figure 2 Effects of selected compounds on Aβ secretion. HEK 293 cells overexpressing 
the Swedish mutation of APP were incubated with in the presence of the test compounds. 
After two days of incubation the amount of soluble Ab40 peptide in the conditioned 
medium was quantified by the use of a sandwich ELISA (black columns) and the cell 
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viability was monitored with an XTT reduction assay (white columns). All experiments 
were performed in triplicates. The results are normalized to the negative control (DMSO), 
which is set to 1 (not shown). A Results for 10 compounds, which were tested at a 
concentration of 20 µM. The γ-secretase inhibitors VII (γVII) and IX (γIX) were added at 
concentrations of 5 µM and 0.1 µM and served as positive controls for inhibition of Aβ 
secretion. B Dose-dependence of compound 102H6. 
 
 
 
 
 
Table 1 
Confirmation of BACE dependence of freshly dissolved compounds in yeast 
  BACE  Yps1p  Invertase 
  50 µΜ 25 µM 12.5 µM  50 µM 25 µM 12.5 µM  50 µM 25 µM 12.5 µM
24E3 1.059 1.046 1.022  1.024 0.998 0.996  1.044 1.018 1.039 
36D10 1.076 1.028 1.058  0.934 0.875 0.870  0.903 0.889 0.921 
46E8 1.265 1.151 1.143  0.834 0.833 0.847  0.919 0.964 1.122 
48E7* 1.172 1.115 1.108  1.119 1.109 1.133  1.080 1.062 1.024 
73H8** 1.043 1.008 0.972  1.000 0.902 0.952  1.044 0.965 1.012 
77H7 2.107 1.971 1.911  0.900 0.903 0.880  1.053 1.013 1.037 
82F10* 0.998 0.994 0.954  1.078 1.032 1.009  1.113 1.091 1.021 
90C10 1.291 1.152 1.080  0.865 0.847 0.875  0.934 0.964 0.983 
101C3 1.908 2.210 1.738  0.787 0.825 0.811  0.940 0.903 0.927 
102H6** 1.071 1.027 1.047  1.094 0.972 0.977  1.087 1.027 1.058 
103B3 1.233 1.165 1.160  1.098 1.003 1.027  1.071 0.995 0.970 
104G4* 0.966 1.233 0.836  0.863 1.454 1.044  0.960 1.181 0.960 
124C3* 1.004 1.023 1.031  0.977 0.974 0.955  0.987 1.051 1.033 
128D2 1.146 1.104 1.051  0.878 0.839 0.879  0.946 0.897 0.926 
                      
Depicted values represent relative cell densities compared to the negative control (1% DMSO, set to 1) 
of the corresponding strain (BACE1, Yps1p or invertase). Values > 1.05 are heavy typed  
* BACE dependence not confirmed       
** BACE dependence not confirmed, but not rejected     
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Table 2   
   In vitro inhibition of 
BACE1 activity   
Compound Inhibition   
24E3 0% (10 µM)   
36D10 40% (50 µM)   
46E8 0% (20 µM)   
73H8 0% (50 µM)   
77H7 40% (20 µM)   
90C10 0% (50 µM)   
101C3 0% (50 µM)   
102H6 45% (50 µM)   
103B3 20% (50 µM)   
128D2 25% (50 µM)   
      
BACE1 activity was assessed in the presence of the test 
compound (concentration in brackets) by the use of FS-IV 
as a substrate. 
 
 
 
Table 3 
Performance of selected compounds in the different systems 
 Potenial from yeast data   
  
Growth stimulation 
of BACE strain 
BACE-
dependent 
Reduction of Aβ secretion in 
HEK 293 APP(Sw) cells 
In vitro Inhibition of BACE 
cleavage (FS-IV) 
24E3 + Yes 0 0 
36D10 + Yes + ++ 
46E8 ++ Yes 0 0 
73H8 + Yes/No* + 0 
77H7 +++ Yes 0 ++ 
90C10 ++ Yes 0 0 
101C3 +++ Yes + 0 
102H6 + Yes/No* +++ ++ 
103B3 ++ Yes + + 
128D2 ++ Yes + + 
     
 + 5-10%  + 10-25% + 20-30% 
 ++ 10-30%  ++ 25-50% ++ 30-50% 
 +++ 30-100%  +++ 50-100%  
     
* BACE-dependent in first, but not in second test  
 54
3.2.5. References 
Burke, D., Dawson, D., and Stearns, T. (2000). A Cold Spring Harbor laboratory course 
manual. Methods in Yeast Genetics.  
 
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-
Pelfrey, C., Lieberburg, I., and Selkoe, D. J. (1992). Mutation of the β-amyloid precursor 
protein in familial Alzheimer's disease increases β-protein production. Nature 360, 672-
674. 
 
Dovey, H. F., John, V., Anderson, J. P., Chen, L. Z., de Saint Andrieu, P., Fang, L. Y., 
Freedman, S. B., Folmer, B., Goldbach, E., Holsztynska, E. J., et al. (2001). Functional γ-
secretase inhibitors reduce β-amyloid peptide levels in brain. J. Neurochem. 76, 173-181. 
 
Durkin, J. T., Murthy, S., Husten, E. J., Trusko, S. P., Savage, M. J., Rotella, D. P., 
Greenberg, B. D., and Siman, R. (1999). Rank-order of potencies for inhibition of the 
secretion of Aβ 40 and Aβ 42 suggests that both are generated by a single γ -secretase. J. 
Biol. Chem. 274, 20499-20504. 
 
Emter, R., Heese-Peck, A., and Kralli, A. (2002). ERG6 and PDR5 regulate small 
lipophilic drug accumulation in yeast cells via distinct mechanisms. FEBS Lett. 521, 57-
61. 
 
Gaber, R. F., Copple, D. M., Kennedy, B. K., Vidal, M., and Bard, M. (1989). The yeast 
gene ERG6 is required for normal membrane function but is not essential for biosynthesis 
of the cell-cycle-sparking sterol. Mol. Cell. Biol. 9, 3447-3456. 
 
Ghosh, A. K., Shin, D., Downs, D., Koelsch, G., Lin, X., Ermolieff, J., and Tang, J. 
(2000). Design of potent inhibitors for human brain memapsin 2 (β-secretase). J. Am. 
Chem. Soc. 122, 3522-3523. 
 
Gietz, D., St Jean, A., Woods, R. A., and Schiestl, R. H. (1992). Improved method for 
high efficiency transformation of intact yeast cells. Nucleic Acids Res. 20, 1425. 
 
Grüninger-Leitch, F., Schlatter, D., Kung, E., Nelbock, P., and Dobeli, H. (2002). 
Substrate and inhibitor profile of BACE (β-secretase) and comparison with other 
mammalian aspartic proteases. J. Biol. Chem. 277, 4687-4693. 
 
Janzen, W. P. (2002). High throughput screening: Methods and protocols. Humana Press 
190. 
 
Kolaczkowski, M., Kolaczowska, A., Luczynski, J., Witek, S., and Goffeau, A. (1998). In 
vivo characterization of the drug resistance profile of the major ABC transporters and 
other components of the yeast pleiotropic drug resistance network. Microb. Drug Resist. 
4, 143-158. 
 55
 
Lüthi, U., Schaerer-Brodbeck, C., Tanner, S., Middendorp, O., Edler, K., and Barberis, 
A. (2003). Human β-secretase activity in yeast detected by a novel cellular growth 
selection system. Biochim. Biophys. Acta 1620, 167-178. 
 
Middendorp, O., Ortler, C., Neumann, U., Paganetti, P., Lüthi, U., and Barberis, A. 
(2004). Yeast growth selection system for the identification of cell-active inhibitors of β-
secretase. Biochim. Biophys. Acta 1674, 29-39 
 
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., 
Dovey, H. F., Frigon, N., Hong, J., et al. (1999). Purification and cloning of amyloid 
precursor protein β-secretase from human brain. Nature 402, 537-540. 
 
Steinhilb, M. S., Turner, R. S., and Gaut, J. R. (2000). The protease inhibitor, MG132, 
blocks maturation of the amyloid precursor protein Swedish mutant preventing cleavage 
by β-secretase. J. Biol. Chem. 276, 4476-4484. 
 
Storici, F., Lewis, L. K., and Resnick, M. A. (2001). In vivo site-directed mutagenesis 
using oligonucleotides. Nat. Biotechnol. 19, 773-776. 
 
Urech, D. M., Lichtlen, P., and Barberis, A. (2003). Cell growth selection system to 
detect extracellular and transmembrane protein interactions. Biochim Biophys Acta 1622, 
117-127. 
 
 56
Part 3.3. 
Selection of ankyrin repeat protein-based inhibitors of β-
site cleavage 
 
Oliver Middendorp*, H. Kaspar Binz**, Patrick Amstutz**, Alcide Barberis*, and 
Andreas Plückthun** 
 
* ESBATech AG, Wagistrasse 21, CH-8952 Zürich-Schlieren, Switzerland 
** University of Zurich, Winterthurerstrasse 190, CH-8051 Zürich, Switzerland 
 57
3.3. Selection of ankyrin repeat protein-based inhibitors of β-site 
cleavage 
3.3.1 Abstract 
We performed a screening to identify ankyrin repeat (AR) protein-based inhibitors of 
BACE1. A combination of in vitro selection for BACE1 binding AR proteins by 
ribosome display with a subsequent functional selection in yeast yielded BACE1 binding 
AR proteins that inhibit the cleavage of a BACE1 substrate both in vivo and in vitro. 
Further analysis however revealed that the observed inhibition by selected proteins rather 
relied on the interference with the substrate than on impairing BACE1 function directly.  
3.3.2. Introduction 
Ankyrin repeat (AR) proteins are found in virtually all phyla and are expressed as 
nuclear, cytosolic, secreted or transmembrane proteins (Bork, 1993). Variable numbers of 
the usually 33 amino acid ARs build topologically well defined stacks, so-called AR 
domains, the function of which is to mediate specific protein-protein interactions. This 
evolutionary approved concept was exploited to generate combinatorial libraries of 
consensus-designed AR proteins (Binz et al., 2003). By sequence and structure analyses, 
a AR module was designed with invariable framework residues and randomized potential 
interaction residues. This module was cloned in varying numbers between terminal 
capping ARs, leading to combinatorial libraries of AR proteins of varying repeat 
numbers. Determination of the crystal structure of the unselected library member E3_5 
and analysis of several randomly picked library members revealed an AR domain fold 
and favorable thermodynamic stabilities of the designed AR proteins (Binz et al., 2003; 
Kohl et al., 2003). Binding AR proteins with nanomolar affinities against several globular 
proteins were selected from the consensus AR protein libraries by using ribosome display 
(Binz et al., 2004).  
In an attempt to identify AR protein-based inhibitors of BACE1 we combined in vitro 
ribosome-display selection for BACE1 binding AR proteins with a subsequent functional 
selection for proteins that inhibit the cleavage of a BACE1 substrate. The advantage of 
this combination is that the in vitro selection step decreases the library complexity to a 
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size, which is suitable for the subsequent in vivo screening. At the same time, the in vitro 
selection increases the chance of finding functional AR protein inhibitors, since the 
selected proteins already show BACE1 binding. The functional selection was performed 
in yeast using the “Yeast growth selection system for the identification of cell-active 
inhibitors of β-secretase” (Middendorp et al., 2004), which is described in part 3.1. of 
this thesis.  
3.3.3. Results 
In vitro selection of BACE1 binders 
The AR protein libraries we used in our experiment were termed N2C and N3C, 
reflecting the content of an N-terminal capping AR, two or three randomized AR 
modules and a C-terminal capping AR. The estimated diversity of the libraries is at least 
1010 (Binz et al., 2004). Three independent selections comprising four rounds of 
ribosome display each were performed against the BACE1 ectodomain using twice the 
N3C library and once the N2C library. We observed a rapid and specific enrichment of 
binding throughout the selection process. After four selection rounds, 16 clones from 
each selection were analyzed with an enzyme-linked immunosorbent assay (ELISA) for 
BACE1 ectodomain binding using Escherichia coli (E. coli) crude cell extract. Figure 1 
shows that of 16 clones from the N2C pool, 11 specifically (as compared to binding to 
neutravidin) bound BACE1; one bound neutravidin as well and 4 gave no signal above 
background. For the two N3C selections there were 15 and 16 specific BACE1 binding 
AR proteins among the analyzed clones. This result indicates that the in vitro selections 
indeed enriched for proteins with BACE1-binding properties. 
 
Subcloning of BACE1 binding AR proteins into an ER targeted yeast expression library 
To select for BACE1 binding AR proteins with inhibitory properties using the yeast 
selection system, they had to be targeted to the secretory pathway, where the β-secretase 
cleavage of the invertase-APP reporter fusion protein occurs (Lüthi et al., 2003). In order 
to find an efficient way to direct AR proteins to the yeast ER, the amino acids 1-35 of the 
yeast invertase (Suc2p), which comprise the signal peptide (amino acids 1-19), were 
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fused N-terminally to the RGSHis6-tagged AR protein E3_5 (Figure 2A), which is an 
unselected member of the N3C library. This construct, named Suc2p(1-35)-RGSHis6-
E3_5, was expressed in yeast and detected by the use of an αRGSHis6-antibody in a 
Western blot analysis of yeast crude cell extract. This expression analysis revealed two 
bands of comparable intensity (figure 2B, lane 1). Analysis of an endoH glycosylase-
treated aliquot of the same crude cell extract revealed a decrease of the intensity of the 
upper band compared to the untreated sample (figure 2B, lane 2), indicating that the 
upper band could represent a glycosylated molecule population and consequently that the 
fusion protein reached the ER, since this is the organelle, where N-glycosylation occurs. 
In fact, the 35 amino acid Suc2p peptide contain a potential N-glycosylation site at 
position 23. As a further control, we expressed a version of Suc2p(1-35)-RGSHis6-E3_5, 
which is deleted for the first 19 amino acids (named Suc2p(20-35)-RGSHis6-E3_5; figure 
2A). Expression of this construct revealed one band on the Western blot, which migrated 
at the same level as the lower band of the doublets observed for Suc2p(1-35)-RGSHis6-
E3_5 (figure 2B, lane 3). Therefore, this lower band could represent Suc2p(1-35)-
RGSHis6-E3_5, from which the signal peptide was removed during the translocation to 
the ER. Taken together, the results of this Western blot analysis provide good evidence 
that the AR protein E3_5 was indeed translocated to the yeast ER by the Suc2p(1-35) 
leader sequence. 
We hence subcloned the DNA pools originating from the three independent in vitro 
selections against the BACE1 ectodomain into this plasmid (replacing E3_5). Like this, 
libraries named L4, L5 and L6, with diversities of about 1.5·105 were generated, suitable 
for in vivo selections in yeast. 
Functional selection of putative BACE1 inhibitors 
In the yeast selection system, active BACE1 liberates the invertase moiety from an 
invertase-APP fusion reporter protein (Lüthi et al., 2003). The liberated invertase activity 
is secreted to the periplasmic space, where it encounters and hydrolyzes sucrose, thereby 
generating fructose and glucose (the selection medium contains 5% sucrose, 2% 
galactose and lacks histidine). The freshly generated glucose dominantly blocks the 
transcription of the growth selection marker HIS3, which is under the control of the 
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GAL1-10 promoter (PGAL1-10-HIS3). Expression of the HIS3 gene, however, is required 
for growth on histidine-depleted medium. If no invertase activity is secreted, and 
consequently no glucose is generated, galactose induces the expression of HIS3 from the 
GAL1-10 promoter and cells can grow on histidine-depleted medium. Hence, in the 
presence of active BACE1, invertase activity is secreted and growth on histidine-depleted 
medium is repressed by the freshly generated glucose. If a yeast cell is transformed with 
an inhibitory AR protein, the secretion of invertase activity is impaired and the cell can 
form a colony. One limitation of this selection system is the so-called cross-repression, 
which means that diffusing glucose generated by neighboring cells can repress the growth 
of a positive clone. This produces the paradox situation, in which a high transformation 
efficiency can yield less positives than a low transformation efficiency. Ideally, the 
transformation efficiency should be about 5000 evenly spread clones per 15 cm plate 
(data not shown). 
The growth selection marker PGAL1-10-HIS3 was stably integrated into the genome of the 
selection yeast strain (Biscre1), whereas the invertase-APP fusion protein, BACE1 and 
the libraries were expressed from episomal plasmids (see materials and methods). We 
performed three screening experiments, one for each library. The screening of the L4 
library had a scale of 11 plates; the screenings of the L5 and the L6 library were 
performed with 5 plates each. For the individual performances of the three screenings see 
Table1. In total we screened about 1.7⋅105 transformants, which revealed 266 putative 
positive clones after three days of incubation at 30°C.  We picked 127 colonies and 
restreaked them on plates containing selection medium - all of them grew up again. From 
60 clones out of these 127, we could rescue a plasmid with a restriction digest pattern 
corresponding to the one of a library plasmid. After retransformation of the rescued 
plasmids, 42 gave rise to colony formation again. Figure 3A shows a representative 
example of a retransformation of a selected AR protein (L4_36), which gives rise to 
colony formation. The sizes of the colonies are comparable to the ones formed by cells 
expressing an inactive version of BACE1 (D93N mutant) and no AR protein. The 
colonies formed by cells expressing active BACE1 and no AR protein, or active BACE1 
and an unselected AR protein (E3_5), are both hardly visible (small size). 
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Selected ankyrin repeat proteins stimulate growth of yeast cells in a BACE1-dependent 
manner 
In order to produce a provisional ranking of the selected AR proteins, their growth 
restoration capability was quantified by means of a liquid growth assay. Pre-cultures with 
unselective medium were inoculated with Biscre1 cells expressing invertase-APP, 
BACE1 and the selected AR proteins. Equal amounts of exponentially growing pre-
cultures were then used to inoculate cultures with selective medium (histidine-depleted 
medium containing 5% sucrose and 2% galactose). After 26 hours incubation the cell 
densities of the different cultures were determined by measuring OD595 nm and normalized 
to the negative control being a sample that expresses no AR protein. The values obtained 
ranged from 1 to 6. The growth of a control expressing inactive BACE1 (D93N mutant) 
or an empty vector instead of active BACE1 is usually enhanced by a factor of 7 to 8 
compared with the negative control. 37 clones that markedly stimulated growth in this 
experiment were sequenced. 
Although the AR proteins were pre-selected for binding to the BACE1 ectodomain, it 
could still be that the observed growth stimulation in the presence of selected AR proteins 
was caused by a different mode of action than directly impairing BACE1 function. 
Therefore, we examined, whether selected AR proteins would have a similar effect on 
cultures expressing an alternative secretase instead of BACE1. The yeast protease Yps1p 
cleaves APP at the α-site (Zhang et al., 1997) and liberates the invertase moiety from the 
invertase-APP fusion protein (Lüthi et al., 2003). Replacing BACE1 by Yps1p in the 
described liquid growth assay system produces a comparable growth retardation in the 
absence of selected AR proteins. Importantly, the selected AR proteins, which were 
tested, could only rescue the growth of BACE1-expressing cultures, whereas they had no 
effect on Yps1p-expressing cultures (figure 3B). 
In vitro analysis of selected ankyrin repeat proteins 
On the basis of the sequence information of the 37 clones (see supplementary data) we 
chose which candidates to characterize further in vitro. The sequences from the N2C 
library (L5) could be divided into two groups. The first contained eight members, 
whereof two are identical and the remaining differ by only one amino acid from the 
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others. The second group contains only one member (L5_23), which differs in most 
randomized positions from the consensus of the first group. However, we could only 
subclone L5_23 in a bacterial expression vector. For all members of the first group the 
cloning never worked, probably due to a toxic effect for the bacteria. The sequences of 
the N3C (L4 and L6) selections revealed four pairs of identical (or almost identical) 
sequences each, whereas the residual 20 sequences were remarkably different from each 
other. We chose one of the clones from each pair as well as eight further candidates, 
which were chosen due to a good performance in the liquid growth assay or due to 
mutations at framework positions of the AR protein. For one of these 12 candidates, the 
subcloning failed similar as described for the L5 clones. Finally, proteins of 12 
candidates were purified and subjected to further in vitro characterization. 
The proteins were expressed in soluble form in the cytoplasm of E. coli and could be 
purified to homogeneity in a single purification step via binding of the RGSHis6-tag to an 
immobilized metal ion affinity chromatography (IMAC) column (data not shown). 
ELISA analysis of the purified proteins revealed that out of 12 there were eight, which 
specifically (as compared to binding to neutravidin) bound to the BACE1 ectodomain at 
pH 7.4 and at pH 4.5 (figure 4A), which is the pH that was used for BACE1 enzymatic 
activity assays. The inhibitory potentials of the selected AR proteins were assessed by a 
FRET assay, in which the substrate is a modified peptide harboring the Swedish mutation 
(Citron et al., 1992) of the APP β-site. This peptide is coupled to a fluorescence group 
and a quenching group, which become separated upon cleavage resulting in an increase 
of fluorescence signal. Figure 4B shows an overview of BACE1 kinetic activities in the 
presence of 1 µM of selected AR proteins. Whereas for the unselected AR proteins E2_5 
and E3_5 there was no significant inhibition observed, most selected proteins revealed a 
modest, but significant reduction of signal gain per time (initial velocity). This reduction 
was about 15% in average. The highest reduction was observed for L4_65, for which a 
concentration dependence experiment was performed (figure 4C). The initial velocity of 
the reaction was indeed decreasing with increasing concentrations of L4_65, but in 
addition we also observed a concentration dependent increase of the fluorescence signal 
measured at the beginning of the reaction (figure 4D). Also the other selected AR 
proteins caused an increased start signal in the FRET assay at a concentration of 1 µM 
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when compared to samples with buffer alone or 1 µM of the unselected library members 
E2_5 and E3_5 (data not shown). 
We further examined this phenomenon by the use of a product standard, which consists 
of the fluorescence group coupled to the N-terminal half of the substrate and thereby 
mimics the signal originating from the cleaved substrate. The outcome of this experiment 
was that the selected AR proteins enhanced the fluorescence signal, when incubated with 
the uncleaved substrate, but not, when incubated with the product standard. An 
explanation for this would be that the selected AR proteins somehow interfere with the 
intramolecular quenching of the substrate. However, from these results we could not 
conclude whether the observed interference of selected AR proteins with the substrate 
would also influence the increase of signal over time. Therefore we developed a 
cathepsin D assay. Cathepsin D is like BACE1 an aspartic protease and it is known that it 
cleaves the Swedish mutation of APP at the β-site (Grüninger-Leitch et al., 2000). 
Therefore we tested our BACE1 FRET substrate for cleavage by cathepsin D and found 
that it was cleaved at the same conditions as used for cleavage by BACE1. In order to 
obtain a comparable velocity of substrate turnover for the BACE1 and the cathepsin D 
reaction, we used the double substrate concentration for the cathepsin D assay (this was 
necessary because we performed the reaction at pH 4.5, which is optimal for BACE1 in 
vitro cleavage, and not at pH 3.5, which would have been optimal for cathepsin D). 
Figure 4D shows that in the presence of 1 and 5 µM L4_65 the cathepsin D-mediated 
increase of fluorescence signal over time is inhibited in a concentration-dependent 
manner. We observed also a small, but significant concentration-dependent inhibition in 
the presence of 1 and 5 µM of the unselected E3_5 protein. In addition we tested for 
inhibition of cathepsin D-cleavage by 5 µM L4_37 and 4 µM L6_11, which were found 
to be 70%, and 34%, respectively (data not shown). 
Is the growth stimulation in yeast by selected ankyrin repeat proteins dependent on the 
sequence of the substrate? 
We wanted to test the hypothesis whether the growth stimulation of yeast cultures by 
selected AR proteins was dependent on a putative interaction of the AR protein with the 
invertase-APP fusion protein rather than on the binding of the AR proteins to BACE1. 
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Therefore we made use of a modified invertase-APP fusion protein, in which the residues 
p4-p4’ of the β-site were substituted by an optimized artificial BACE1 cleavage site 
(Turner et al., 2001). We compared this construct named invertase-APP(art) in a growth 
assay to the construct invertase-APP(Sw), which was used in all the previously described 
yeast experiments and which harbors the Swedish mutation at the β-site (figure 5A). 
Whereas in the absence of AR proteins the two construct performed in a comparable 
manner – with BACE1 as well as without BACE1 – the growth stimulation by selected 
AR proteins was more pronounced with invertase-APP(Sw) (figure 5B). This result 
indicates that the growth stimulation by selected AR proteins is not completely dependent 
on the exact sequence of invertase-APP(Sw). Unexpectedly, in the presence of the 
unselected AR proteins E2_5 and E3_5 the growth of cultures expressing invertase-
APP(art) was reduced compared to cultures expressing invertase-APP(Sw), while there 
was no difference in the absence of AR proteins (Although small, this seems to be a true 
effect, since the repetition of the experiment produced exactly the same picture).  
In order to visualize the cleavage of the two different invertase-APP constructs in the 
presence or absence of selected AR proteins, we performed Western blot analysis to stain 
the APP C-terminal fragments (CTFβ) that were produced upon BACE1 cleavage. Figure 
5C shows that the stainings of CTFβs originating from invertase-APP(art) are generally 
more pronounced compared the CTFβs from invertase-APP(Sw). However, the 
comparison of bands from invertase-APP(Sw) and invertase-APP(art) does not 
necessarily reflect different cleavage efficiencies,  since it could well be that these 
cleavage products have different half-life times in yeast as well. The comparison of bands 
originating from the same construct, however, is valid if the intensities of the bands 
migrating immediately below the 35 kDa marker are taken into account, since these are 
unspecific bands and reflect the relative amounts of samples loaded. This kind of 
evaluation reveals that the cleavage of both, the invertase-APP(Sw) and invertase-
APP(art) is reduced in the presence of the analyzed selected AR proteins, but not in the 
presence of E3_5.  
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3.3.4. Discussion 
The aim of the present work was the identification of AR protein-based inhibitors of 
BACE1. To achieve this, we pursued a stepwise selection approach, in which we first 
selected for a pool of BACE1 binding AR proteins in vitro and then subjected this pool to 
a functional selection in yeast to identify AR proteins that inhibit β-secretase cleavage. 
Our data indicate that the in vitro selection worked efficiently; as among 48 clones 
analyzed before the yeast selection there were 42 binding specifically to BACE1. 
Surprisingly, this ratio was worse after the yeast selection, out of 12 purified proteins 
there were no more than two third specifically binding to BACE1. Further in vitro 
analysis of purified proteins revealed a modest, but significant inhibition of BACE1-
mediated FRET substrate cleavage by all the selected AR proteins. However, at least for 
the selected AR proteins L4_37, L4_65 and L6_11, this inhibition was not BACE1 
specific, as they inhibited also cathepsin D cleavage of the same substrate. Although not 
tested, we believe that this is also the case for the other proteins purified. The reason for 
this is, that in the FRET assay all proteins caused an increase of the fluorescent start 
signal, which was in the case of L4_65 concentration-dependent, indicating that the 
proteins interfere with the FRET substrate. Using two alternative FRET substrates, we 
observed for both unspecific inhibition of the cleavage by unselected AR proteins (data 
not shown). 
These in vitro results give rise to the speculation that also in yeast, the growth 
stimulatory effect by the selected proteins is rather dependent on an interaction of the AR 
protein with the substrate rather than on the interaction with BACE1. The strongest 
argument in favor of this hypothesis is that one third of the purified proteins did not bind 
BACE1 in vitro. However, so far we have no prove for this hypothesis. Replacing 
BACE1 by Yps1p, which cleaves 16 amino acids C-terminal of the β-site, abolished the 
growth stimulatory effect of the tested AR proteins, indicating, that the effect would be β-
site cleavage-specific. Exchanging invertase-APP(Sw) by invertase-APP(art), in which 
eight amino acid residues around the β-site are replaced by an artificial BACE1 cleavage 
sequence, resulted in growth stimulation by selected AR proteins as well - even though 
reduced. This data is difficult to interpret. It can be interpreted in favor of our hypothesis, 
with the explanation that two (maybe critical) amino acid residues of the two cleavage 
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sequences are identical and that also adjacent residues might be important for binding of 
the AR protein to the β-site. Therefore, the selected AR proteins could still, but with 
lower affinity, bind to the artificial β-site. Another suitable explanation for the impaired 
growth restoration of invertase-APP(art) expressing cultures by selected AR proteins, is 
that the artificial sequence is simply more efficiently cleaved, which is the case in vitro 
(Turner et al., 2001). In the presence of the unselected proteins E2_5 and E3_5 the 
growth of cultures expressing invertase-APP(art) is also reduced compared to cultures 
expressing invertase-APP(Sw), which is in accordance with the second explanation; 
however, in the absence of any AR proteins, there is no more growth difference. The data 
obtained from Western blot analysis (figure 5C) could indicate as well that invertase-
APP(art) is more efficiently cleave than invertase-APP(Sw), but, as mentioned above, 
this data could also reflect different half-life times of the C-terminal cleavage products in 
yeast.  
The bottom line of aforesaid Western blot analysis is that the analyzed selected AR 
proteins indeed seem to prevent β-site cleavage of both substrates. The clones analyzed 
by Western blot are all competent of binding BACE1 ectodomain in vitro. If the AR 
proteins fused to the Suc2p leader sequence are still competent of binding membrane-
bound BACE1 expressed in yeast, we do not know. Further experiments, such as co-
immunoprecipitations or GST pull down assays, are necessary to investigate the 
mechanism by which the selected AR proteins prevent the cleavage of invertase-APP in 
yeast. 
Although the actual yeast data does not provide evidence for the hypothesis that β-site 
cleavage is prevented via binding of selected proteins to the substrate, it does not exclude 
this possibility either and the in vitro analysis of purified proteins supports this 
hypothesis. How could it come that all the purified proteins seem to interfere with the 
substrate? Maybe the AR protein scaffold has an inherent tendency for binding to the 
amino acid sequence around the β-site. Furthermore, the character of the amino acid 
residues at certain randomized positions would modulate this binding tendency and the 
yeast system would have selected for those with enhanced binding properties. A possible 
hint for this scenario is that E3_5 also weakly interferes with the FRET assay and that 
this interference is more evident in the cathepsin D assay, in which we used the double 
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substrate concentration. A high abundance of proteins with enhanced affinities for the 
substrate would titrate out the BACE1 inhibitors from the pool of analyzed positives. 
This putative problem could be overcome by analyzing more positives, which is quite 
laborious since they all have to be at least partially purified, or alternatively by finding 
conditions that no more allow for growth of cultures expressing AR proteins, which were 
selected with the described conditions, but still allow for growth in the absence of 
BACE1. 
In summary, the in vitro selection worked, as there were specific BACE1 binders 
identified – the in vivo selection worked as well, since it revealed inhibitors of β-site 
cleavage. The combination of the two systems, however, did not facilitate the preferred 
identification of BACE1 inhibitors, possibly due to a predisposition of the used AR 
protein format to bind to the β-secretase cleavage site of APP. 
3.3.5. Materials and methods 
Ribosome-display selection of BACE1 binding AR proteins 
Human BACE1 was purchased from oncogene research products (San Diego, CA, 
USA). The ribosome-display selections were essentially performed as described (Binz et 
al., 2004) with the following modifications: For the panning, 100 µl/well 65 nM BACE1 
was immobilized directly on a maxisorp surface (Nunc) at 4°C overnight. All wells were 
blocked with 300 µl 0.5% BSA in 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.05% 
Tween 20 for 1 hour at room temperature prior to selection. The selection comprised two 
prepanning steps (1 hour in a neutravidin coated well; 45 minutes in a phage lambda 
protein D coated well) (Binz et al., 2004) followed by the 45 minutes selection step in a 
BACE1 coated well. Four ribosome-display selection rounds were performed with the 
N2C and N3C AR protein libraries (Binz et al., 2004) prior to analyzing single selected 
library members for BACE1 binding. Two independent selections were performed with 
the N3C library. The selected DNA pools were subcloned into pQE30 (QIAgen), 
followed by a crude extract ELISA screening for BACE1 binding (see ref. (Binz et al., 
2004); Fig. 1). Quantitative ELISAs were performed basically as described (see ref. 
(Binz et al., 2004); Fig. 4), with the following modifications: Two different binding 
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buffers were used during the 40 minutes binding step at 4°C {PBS pH 7.4 (8 mM 
Na2HPO4, 2 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl) or 100 mM NaOAc pH 4.5}. 
Apart from this, all blocking, washing and incubation steps were in PBS supplemented 
with 0.05% Tween 20. AR protein concentration was 100 nM. BACE1 was immobilized 
as described above. 
Yeast expression plasmids 
The yeast expression plasmids for BACE1 (BACE-ACT1), invertase-APP(Sw) 
(Suc2pAPPSw) and Yps1p, as well as the yeast strain Biscre1 have been described in part 
3.1. of this thesis. The plasmid expressing invertase-APP(art) is a Suc2pAPPSw 
derivative, which was cloned as follows: A DNA fragment encoding the APP amino 
acids 590-695 harboring the alternative cleavage site was amplified by means of PCR. 
The primers used for this PCR reaction were oligo #5651 (gctgcggccgctgagatctctgaaatt 
gatttgatggttttggatcgacatgactcaggatatgaag), which contains the DNA code for the 
alternative cleavage site as well as homologies to the APP nucleotide sequence, and the 
oligo #5458 (tcacctacttagtcgacttaagg), which anneals 3’ of the APP nucleotide sequence 
of Suc2pAPPSw. The template was Suc2pAPPSw. The resulting DNA fragment was 
cloned into the NotI/SalI sites of Suc2pAPPSw. Suc2p(1-35)-RGSHis6-AR fusion proteins 
are expressed from an ACT1 promoter on a 2 micron plasmid with a LEU2 marker, which 
was constructed the following: The 1175 bp EcoRI/SphI cassette of pDU10 (Urech et al., 
2003) was ligated into the EcoRI/SphI sites of YEplac181 (NCBI database: X75460) 
producing plasmid#21. The DNA sequence coding for Suc2p(1-35)-RGSHis6 was 
amplified by a PCR reaction of partially self-complementary oligos (#6639: 
ttttctagaatgcttttgcaagctttccttttccttttggctggttttgcagccaaaatatctgcatcaatgacaaacgaaactagcgat, 
#6640: aaaagatctgtgatggtgatggtgatgcgatcctctcatgggtgtgaagtggaccaaaggtctatcgctagtttcgtttg 
tcattgatgc) and cloned into the BglII/XbaI sites of plasmid#21 thereby producing 
plasmid#370 into which the DNA coding for the AR proteins was cloned by means of 
BglII and SpeI sites. For the construction of plasmids expressing fusions with Suc2p(20-
35)-RGSHis6 the self complementary oligos #6641 (ctagaatgtcaatgacaaacgaaactagcga 
tagacctttggtccacttcacacccatgagaggatcgcatcaccatcaccatcaca) and #6642 (gatctgtgatggtgat 
ggtgatgcgatcctctcatgggtgtgaagtggaccaaaggtctatcgctagtttcgtttgtcattgacatt) were cloned into 
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the BglII/XbaI sites of plasmid#370 derivatives, into which the DNA coding for the AR 
proteins was already inserted.  
Construction of the yeast expression libraries: 2 kbp of spacer DNA were inserted into 
the BglII/SpeI sites of plasmid#370 to produce a vector, the digestion of which by 
BglII/SpeI can be readily controlled. For the generation of the library, the BglII/SpeI 
spacer fragment was replaced by the DNA fragments resulting from ribosome-display 
selections to generate the libraries L4 (N3C(2) selection), L5 (N2C selection) and L6 
(N3C(1) selection). Transformation into E. coli (KC8) yielded 1.64⋅105 colonies for L4, 
1.5⋅105 colonies for L5 and 1.45⋅105 colonies for L6, from which the plasmids were 
prepared using the QIAgen “Hispeed Plasmid Maxi Kit”. 
Yeast growth selections 
The yeast strain Biscre1, the construction of which has been described in part 3.1. of 
this thesis, was used for all yeast experiments described in this section. Transformation of 
yeast cells was performed following the lithium acetate method (Gietz et al., 1992). 
Media were prepared according to Burke et al. (Burke et al., 2000). For the yeast 
selection, Biscre1 cells pre-transformed with BACE-ACT1 were supertransformed with 
Suc2pAPPSw and one of the libraries L4, L5 or L6. The transformed yeast cells were 
resuspended in YPAD, incubated for three hours at 30°C and washed with H2O before 
they were plated on 14.5 cm dishes with –his –leu –ura –trp 5% sucrose 2% galactose 
medium. After 3-4 days incubation at 30°C upcoming colonies were picked and 
restreaked on –his –leu –ura –trp 5% sucrose 2% galactose medium. From these restreaks 
there were single clones isolated und subjected to the plasmid rescue protocol.  
Growth assays in liquid medium were performed in microtiter plates basically as 
described in part 3.1. of this thesis with the following modifications: The selection 
medium was –his –leu –ura –trp 5% sucrose 2% galactose, the culture volume was 200 
µl. 
Plasmid rescue 
1.5 ml –leu 2% glucose yeast cultures were grown over night at 30°C and spun down in 
microfuge tubes. After decanting the supernatant and addition of glass beads, the samples 
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were vigorously vortexed for 3-5 minutes. The following steps were performed using 
components of the Promega Wizard miniprep kit. After addition of 250 µl lysis solution, 
the samples were gently mixed and incubated for 4 minutes at room temperature before 
350 µl of neutralization solution were added to the samples, which were then centrifuged 
in a microfuge for 10 minutes a full speed. The supernatants were transferred to the 
Promega miniprep spin columns and the plasmid DNA was purified following the 
Promega protocol. The plasmids were eluted with 50 µl TE, of which 10 µl were 
transformed into chemo-competent MC1066 E. coli cells. Plating the transformations on 
M9 –leu plates (Sambrook et al., 1989) allowed for selection of clones harboring yeast 
LEU2 plasmids. 
Western blot analysis 
Whole cell extracts from transformed yeast were prepared as described by Burke et al. 
(Burke et al., 2000). Proteins were separated by SDS PAGE and Western blot analysis 
was performed according to standard procedures. A mouse monoclonal antibody from 
Sigma (A8717) that recognizes residues 676-695 of human APP695 was used at a final 
concentration of 25 ng/ml to detect expression of the CTFβ fragment. RGSHis6-tagged 
AR proteins were detected using 133 ng/ml of an αRGSHis6 antibody (QIAgen, 34650). 
 
FRET assays 
BACE1 FRET assays were performed using a PanVera kit (distributed by Invitrogen, 
P2985). The AR proteins were dissolved in 250 mM NaCl 25 mM Tris⋅HCl pH 8.0 10% 
glycerol and were added as 25 times concentrated solutions to the reaction. BACE1 was 
pre-incubated with the AR proteins for 30 minutes at 30°C before addition of the 
substrate and measuring fluorescence in a microtiter plate reader (Tecan Genios) at an 
excitation wavelength of 535 nm and an emission wavelength of 580 nm. The intial 
velocities were calculated using the values obtained between the 2nd and the 10th minute 
of the reaction. Cathepsin D FRET assays were performed using the same reaction buffer 
and the same FRET substrate as for the BACE1 FRET assay. Recombinant cathepsin D 
was obtained from Sigma (C8696) and used at a final concentration of 10 nM. The FRET 
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substrate was used at a final concentration of 500 nM (which is double as much as for the 
BACE1 assay). 
3.3.6. Figures and tables 
 
Table 1 
Overview of yeast screenings 
Library L4 (N3C) L5 (N2C) L6 (N3C) total 
Scale 11 plates 5 plates 5 plates 21 plates 
Transformants 9900/ plate 6500/ plate 5900/ plate 170'000 
Putative positives 113 72 81 266 
 average per plate 10.3 14.4 16.2  
Colonies picked 79 24 24 127 
Growth after retransformation 24 9 9 42 
Proteins purified 9 1 2 12 
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Figure 1. Crude cell extract ELISA for the identification of BACE1 binding AR proteins 
of the pools of selected AR proteins from the three independent ribosome display 
selections N2C, N3C(1) and N3C(2). Crude cell extracts of E. coli expressing in vitro 
selected AR proteins were probed for binding to neutravidin (white bars) and to BACE1 
ectodomain (black bars). The background signal of the detection antibodies has not been 
subtracted in this representation. 
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Figure 4. Western blot analysis of crude cell extracts of yeast cells expressing an ER 
targeted AR fusion protein. A Schematic drawings of analyzed samples. A portion of the 
Suc2p protein (represented in black, numbers in brackets indicate amino acid positions) 
was fused N-terminally to the RGSHis6-tagged (represented in gray) unselected N3C 
library member E3_5 (represented by 5 white boxes). 1 Putatively glycosylated and ER 
targeted protein. 2 Putatively ER targeted protein, subjected to deglycosylation by endoH 
glycosylase. 3 Truncated protein lacking amino acids 1-19 of the Suc2p portion, 
putatively cytoplasm-resident. B Western blot analysis of the samples described in A. 
The bands were stained by using an αRGSHis6-antibody. 
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Figure 3. Selected AR proteins stimulate growth of Biscre1 cells in a BACE1-specific 
manner. A Growth of differentially transformed Biscre1 cells on selective plates after 
three days incubation at 30°C. All transformants express invertase-APP(Sw). 
Additionally, they express: BACE1 and no AR protein (empty), inactive BACE1 (D93N 
mutant) and no AR protein (empty), BACE1 and the unselected AR protein E3_5 or 
BACE1 and the selected AR protein L4_36. The colony formation induced by L4_36 is 
representative for all the selected AR proteins, which gave again rise to colony formation 
after plasmid rescue. B Growth of differentially transformed Biscre1 cells in selective 
liquid medium after 26 hours incubation at 30°C. All transformants express invertase-
APP(Sw) together with BACE1 (with bars), Yps1p (black bars) or no secretase (gray 
bar). In addition, the yeast cells express one of four different selected AR proteins 
(L4_36, L4_37, L5_27, L6_11) or no AR protein. Growth was determined by measuring 
OD595 nm and normalized to the samples expressing no AR and the respective secretase. 
The sample expressing no secretase was normalized to the growth of the culture 
expressing no AR protein and BACE1. 
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Figure 4. In vitro analysis of purified in vivo selected AR proteins. A BACE1 binding of 
selected AR proteins at pH 7.4 (upper panel) and pH 4.5 (lower panel). 100 nM of AR 
protein each was tested for BACE1 ectodomain (black bars) or neutravidin (white bars) 
binding. The background signal of the detection antibodies has not been subtracted in this 
representation. B Kinetic study of FRET substrate hydrolysis by BACE1 in the presence 
of 1 µM selected or unselected AR proteins. Displayed initial velocity (v0) values of the 
 75
different reactions were normalized to v0 values obtained by control reactions in the 
absence of AR proteins (negative control; dashed line) and represent averages of three 
samples. C Kinetic study of FRET substrate hydrolysis by BACE1 in the presence of 
increasing concentrations (as indicated) L4_65 protein. D Fluorescence signal measured 
at the beginning of the kinetic study shown in C; RFU: Relative fluorescence units. E 
Kinetic study of FRET substrate hydrolysis by cathepsin D in the presence of 1 and 5 µM 
L4_65 or E3_5 protein. Displayed v0 values were normalized to the negative control 
(dashed line). 
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Figure 5 
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Figure 5. Examinations of an artificial BACE1 cleavage site introduced into the 
invertase-APP fusion protein. A Schematic drawings of the two different invertase-APP 
fusion constructs that were used. The two constructs with the invertase moiety 
represented as gray bar and the APP portion represented as white bar are identical except 
for the p4-p4’ sequence of the β-site. The p4-p4’ (Sw) sequence originates from the 
Swedish mutation of APP and was inserted into the invertase-APP(Sw) construct. The 
p4-p4’ (art) is an optimized artificial cleavage site for BACE and was inserted into the 
invertase-APP(art) construct. The vertical arrows indicate the cleavage site; TM: 
Transmembrane domain. B Growth of differentially transformed Biscre1 cells in 
selective liquid medium after 26 hours incubation at 30°C. The transformants contain 
either invertase-APP(Sw) (white bars) or invertase-APP(art) (black bars) together with 
BACE1 (where indicated) or empty vector. In addition, the cells express an unselected 
AR proteins (E2_5, E3_5), a selected AR protein (L4_37, L4_65, L6_11) or no AR 
protein. In this representation there is absolute growth displayed as determined by 
measuring OD595 nm. C Detection of the APP C-terminal fragments (CTFβ) produced by 
β-site cleavage in differentially transformed Biscre1 one cells by Western blot analysis. 
Yeast crude cell extract was produced from the same transformants as described in B. 
The samples were separated on 12% SDS polyacrylamid gel and stained with an antibody 
directed against the APP C terminus. Sw: invertase-APP(Sw); art: invertase-APP(art). An 
arrow indicates the position of the CTFβ on the membrane. 
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4. Conclusions 
The present thesis describes a unique growth readout in yeast for the identification of 
BACE1 inhibitors. From a biological point of view BACE1 is widely considered as an 
ideal drug target for AD therapy. The best progress towards therapeutic inhibition of 
BACE1 has so far been achieved by the use of peptidomimetic compounds. No lead 
structures originating from successful screenings of small molecule libraries have been 
published so far. A potential problem of in vitro screenings might be the artificial nature 
of the reconstituted reaction, in which the naturally membrane-bound substrate is 
represented by a short peptide and the naturally membrane-bound enzyme by the soluble 
BACE1 ectodomain. The difficulties of conventional cell-based assays are demanding 
liquid handling requirements, low throughput and a high rate of false-positive compounds 
that interfere in an unspecific manner with the readout. 
As in the natural situation in mammalian cells, the reconstituted β-site cleavage in yeast 
takes place in topologically extracellular compartments and employs membrane-bound 
substrate and membrane-bound BACE1. In these aspects, the yeast assay is comparable 
to conventional cell-based assays. In a screening for BACE1 inhibitors, however, the 
yeast assay displays considerable advantages over conventional cell-based assays being 
minimized liquid handling, the possibility to rapidly exclude false positives by the use of 
simple controls and the positive growth readout, which allows to excludes toxic 
compounds. 
 The system was initially validated with two bona fide BACE1 inhibitors, which were 
developed by Novartis Pharma. These inhibitors stimulated the growth of BACE1-
expressing yeast cultures in a concentration-dependent manner, whereas they did not 
affect the growth of Yps1p-expressing cultures. In order to further validate the system 
and to identify BACE1 inhibitors, the yeast selection system was applied in a screening 
of 15’000 small molecules. The screening revealed six compounds which significantly 
reduced the secretion of Aβ from HEK 293 APP(Sw) cells. The final proof that they 
indeed affect BACE1 activity by an in vitro assay, however could not yet unambiguously 
be presented. Therefore the identified compounds await further characterization to 
demonstrate inhibition of β-site cleavage in cell culture by Western blot analysis. 
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Due to the limited size of the screened library, the evaluation of the system should not 
be reduced to the potential value of identified compounds. It can be stated that the 
screening did not yield toxic compounds, and a high number of compounds that were 
activating the system independent of BACE1 inhibition could be eliminated due to simple 
specificity controls - as this was predicted. The statistical performance as well as the 
practicability of the system can be considered superior as compared to conventional cell-
based assay. 
In an attempt to further validate the yeast selection system, it was applied for a 
selection on plates to identify artificial ankyrin repeat (AR) protein-based inhibitors of 
BACE1. This selection yielded a number of proteins, which stimulated the growth of 
yeast cells in a β-site specific manner, which means that they did not stimulate the growth 
of Yps1p-expressing cultures, but leaves the possibility that cultures expressing an 
alternative β-secretase would also be stimulated by the selected AR proteins. Further 
experiments would be necessary to determine the exact mode of action of the selected AR 
proteins in yeast. 
In conclusion the data presented in this thesis demonstrate that the yeast selection 
system can be a powerful tool to identify BACE1 inhibitors and therefore the screening 
of larger small molecule libraries with this system would be a valuable approach to 
identify additional small molecule lead structures. 
 83
5. Acknowledgements 
First of all I thank Alcide Barberis, Dominik Escher and Howard Riezman for giving 
me the opportunity to perform my PhD studies at ESBATech. Howard, who accepted me 
as an external PhD student, was always very supportive and helpful, during our six-
monthly meetings as well as whenever I asked a question via email – I usually had the 
answer on my computer within fifteen minutes! Furthermore, the whole company could 
profit from his profound knowledge about the biology of yeast. Alcide, the creative 
scientific officer (CSO) of ESBATech had the idea to revert the growth readout of the 
invertase system by the use of the GAL1/10 promoter, which amazingly turned out to 
work. Not least his great sense of humor made it a pleasure to work with him. It is great 
thank to Dominik that ESBATech could pay my salary every month, despite the fact that 
the company was not generating any revenues ;-). 
Many thanks belong to Urs Lüthi who reconstituted BACE1 activity in yeast during his 
PhD work and whose experience on that topic was of great value for my work. 
ESBATech’s other PhD students David, Tea, Valérie and Stefan (the first), the members 
of the (shrunken) protease unit Karin, Urs and Stefan (the fifth), and all the other people 
at ESBATech contributed a lot to a friendly working atmosphere. I thank them all for the 
good moments we spent together. 
I thank Kaspar Binz with whom I could discuss private as well as scientific issues 
during our bi-weekly training sessions on the dartboard in the pub and who initiated our 
collaboration on the ankyrin repeat protein project. 
I thank all my friends, my sister and my parents for supporting me before, during and 
after the time of my PhD work. 
I thank my girlfriend for loving me. 
 84
6. Attachments 
6.1. Curriculum vitae 
 
Name   Middendorp 
Vornamen  Oliver, Michael 
Geburtsdatum  7. August 1973 in Winterthur ZH 
Heimatort  Klosters GR 
 
Ausbildung 
1980-1986  Primarschule Oberwinterthur 
1986-1989 Sekundarschule Oberwinterthur 
1989-1994 Kantonsschule Im Lee Winterthur, Typus Lehramt 
1994-1999 Studium der Biologie, Universität Zürich 
1994-1995  1. Vordiplom 
1995-1996  2. Vordiplom 
1996-1999 Diplomstudiom der Molekularbiologie mit den  
Nebenfächern Biochemie und Immunologie 
 
Diplomarbeit: “Generation of Mouse Embryonic Stem Cells with 
Mutated p300“ unter der Leitung von Dr. Richard Eckner, 
begutachted von Prof. Dr. Walter Schaffner 
 
1999-2000 Fachdidaktik Biologie, Universität Zürich 
 
2001-jetzt Dissertation in der Biotechnologie-Firma ESBATech AG, 
Schlieren, unter der Leitung von Dr. Alcide Barberis (ESBATech 
AG) und Prof. Howard Riezman (Biozentrum, Basel) 
 
Titel der Dissertation: “Yeast growth selection system for the 
identification of cell-active inhibitors of β-secretase” 
 85
6.2. Publication list 
 
Middendorp, O., Ortler, C., Neumann, U., Paganetti, P., Lüthi, U., and Barberis, A. 
(2004). Yeast growth selection system for the identification of cell-active inhibitors of β-
secretase. Biochim. Biophys. Acta 1674, 29-39 
 
Middendorp, O., Lüthi, U., Hausch, F., and Barberis, A. (2004). Searching for the most 
effective screening system to identify cell-active inhibitors of β-secretase. Biol. Chem. 
385, 481-485 
 
Lüthi, U., Schaerer-Brodbeck, C., Tanner, S., Middendorp, O., Edler, K., and Barberis, 
A. (2003). Human β-secretase activity in yeast detected by a novel cellular growth 
selection system. Biochim. Biophys. Acta 1620, 167-178 
 
6.3. Scientific conferences 
 
Growth and Death in the nervous system, St. Mortitz, March 2004 
 
Yeast 2003 Conference, Göteborg, June 2003 
 
